AU2013205400A1 - Antigenic Polypeptides - Google Patents

Abstract

H:Mar~inienveven\NRonblIDCC\AAR\5II99816_DOC-2414/2013 -21B The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods of 5 manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides.

Description

ANTIGENIC POLYPEPTIDES This application is a divisional of Australian Application No. 2010200510 which is a divisional application of Australian Application No. 2007200937, which is a divisional of Australian Patent No. 2001274248 the entire contents of which are incorporated herein by reference. The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; 5 recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides. Microbial organisms cause a number of fatal or debilitating diseases which affect many millions of people around the world. Currently methods to control microbial 10 organisms include the use of antimicrobial agents (antibiotics) and disinfectants. These have proved to be problematic since exposure to these agents places a significant selection pressure resulting in the creation of resistant microbes which can avoid the effects of the antimicrobial agent(s). For example, recently it has been discovered that microbial organisms have become resistant to triclosan, an agent 15 added to many disinfectants used in households and industrial environments. An arguably greater problem is the evolution of antibiotic resistant strains of a number of significant pathogenic microbes. '20 For example, and not by way of limitation, it is estimated that .there are up to 50 million people world-wide infected with drug resistant tuberculosis (TB) (Figures from the World Health Organisation, 1998). In the past the use of antibiotics to treat TB relied on the administration of single drugs (eg ethionamide) which promoted a relatively high frequency of resistance. For this reason,. combinations of drugs are 25 now used to treat tuberculosis. However the fatality rate in cases caused by strains that are resistant to at least one drug used to treat tuberculosis still approaches 50% even when treatment is given. Mycobacterium tuberculosis, the causative agent of TB, is a slow growing bacteria and takes a long time to kill. Therefore, for a drug combination to be effective a person with TB Miust take the drug combination daily 30 for at least six months. Accordingly, patients frequently have to take two or more pills daily and this requires a regimented dosage over a relatively long period of treatment. Many patients take the medications only intermittently and therefore do not finish the full course of therapy to completely eradicate the M tuberculosis infection. Moreover, TB is strongly associated with HIV infection and therefore the establishment of TB is strongly correlated with immunosuppression. 5 Vaccination against TB has been available for many years. The bacillus calmette and guerin (BCG) vaccination has been widely used throughout the world for a long time because it is a safe and inexpensive means to vaccinate large numbers of people who potentially could contract TB. BCG is derived from live, attenuated strains of 10 Mycobacterium bovis. However the impact of vaccination on the infectious forms of TB is minimal and BCG has therefore contributed little to the overall control of the disease. A further example of a pathogenic organism which has developed resistance to 15 antibiotics is Staphylococcus aureus. S.aureus is a bacterium whose normal habitat is the epithelial lining of the nose in about 20-40% of normal healthy people and is also commonly found on people's skin usually without causing harm. However, in certain circumstances, particularly when skin is damaged, this germ can cause infection. This is a particular problem in hospitals where patients may have surgical 20 procedures and/or be taking immunosuppressive drugs. These patients are much more vulnerable to infection with Saureus because of the treatment they have received. Resistant strains of S.aureus have arisen in recent years. Methicillin resistant strains are prevalent and many of these resistant strains are also resistant to several other antibiotics. Currently there is no effective vaccination procedure for S. 25 aureus. In the US, S.aureus infections are the cause of 13% of the two million hospitalised infections each year. This represents 260,000 people with an infection of S aureus, of which 60-80,000 die. S aureus is therefore a major human pathogen capable of causing a wide range of 30 life threatening diseases including septicaemia, endocarditis, arthritis and toxic shock. This ability is determined by the versatility of the organism and its arsenal of 2 components involved in virulence. Pathogenicity is multifactorial and no one component has shown to be responsible for a particular infection, see Projan, SI. & Novick, R.P. (1997) in The Staphylococci in Human Disease (Crossley, K.B. & Archer, G.L., eds.) pp.55-81. 5 At the onset of infection, and as it progresses, the needs and environment of the organism changes and this is mirrored by a corresponding alteration in the virulence determinants which S aureus produces. At the beginning of infection it is important for the pathogen to adhere to host tissues and so a large repertoire of cell surface 10 associated attachment proteins are made, These include collagen-, fibrinogen- and fibronectin-binding proteins. The pathogen also has the ability to evade host defences by the production of factors that reduce phagocytosis or interfere with the ability of the cells to be recognised by circulating antibodies. 15 Often a focus of infection develops as an abscess and the number of organisms increases. S, aureus has the ability to monitor its own cell density by the production of a quorum sensing peptide. Accumulation of the peptide, associated with physiological changes brought about by the beginning of starvation of the cells, elicits a switch in virulence determinant production from adhesins to components 20 involved in invasion and tissue penetration. These include a wide range of hemolysins, proteases and other degradative enzymes. During the process of any infection the virulence determinants made by S. aureus are produced in response to environmental and physiological stimuli. These stimuli 25 will be dependent on the niche within the body and will change as the infection progresses. Little is known of the conditions in vivo and it is likely that some components are produced solely in this environment. These are therefore potential vaccine components, which could not be discovered by previous techniques. 30 3 One of the most important developments in recent medical history is the development of vaccines which provide prophylactic protection from a wide variety of pathogenic organisms. Many vaccines are produced by inactivated or attenuated pathogens which are injected into an individual. The immunised individual responds 5 by producing both a humoral (antibody) and cellular (cytolytic T cells, CTI's) response. For example, hepatitis vaccines are made by heat inactivating the virus and treating it with a cross linking agent such as formaldehyde. An example of an attenuated pathogen useful as a vaccine is represented by polio vaccines which are produced by attenuating a live pathogen. 10 However the use of attenuated organisms in vaccines for certain diseases is problematic due to the lack of knowledge regarding the pathology of the condition and the nature of the attenuation. For certain viral agents this is a particular probleni since viruses, in particular retroviruses, have an error prone replication cycle which 15 results viable mutations in the genes which comprise the virus. This can result in alterations to antigenic determinants which have previously been used as vaccines. An alternative to the use of inactivated or attenuated pathogens is the identification of pathogen epitopes to which the immune system is particularly sensitive. In this regard many pathogenic toxins produced by pathogenic organisms during an 20 infection are particularly useful in the development of vaccines which protect the individual from a particular pathogenic organism. The development of so-called subunit vaccines (vaccines in which the immunogen is a fragment or subunit of a protein or complex expressed by a particular pathogenic 25 organism) has been the focus of considerable medical research. The need to identify candidate molecules useful in the development of subunit vaccines is apparent not least because conventional chemotherapeutic approaches to the control of pathogenic organisms has more recently been stymied by the development of antibiotic resistance. A number of methods have been developed to identify potential antigenic 30 polypeptides which can be used as a vaccine. One such method is disclosed herein. 4 It has been known for many years that tumour cells produce a number of tumour cell specific antigens, some of which are presented at the tumour cell surface. The immune system recognises these antigens as foreign thereby resulting in the production of antibodies to self antigens, so called autoantibodies or autologous 5 antisera. One such technique is Serological identification of antigens by recombinant Expression Cloning, abbreviated to SEREX. 10 Typically, the technique involves the extraction of RNA from tumour tissue followed by the selective enrichment of mRNA from the isolated total RNA. The mRNA is reverse transcribed into cDNA using viral reverse transcriptase. The cDNA thus synthesised is subcloned into an expression vector and transfonned into an appropriate bacterial strain. The transformed bacteria are plated onto a suitable 15 nutrient agar and under appropriate growth conditions the subcloned cDNA is expressed from the expression vector in the bacterial cell. The cells are lysed naturally by the use of phage based expression vectors, for example X phage or phagemid based vectors, which through their lytic cycle cause cell lysis. The released polypeptides are transferred to a suitable membrane support (i.e. 20 nitrocellulose, nylon) and exposed to autologous antisera from the patient from which the tumour tissue was originally isolated. The immunoscreening methodology allows the identification of genes that are over expressed or inappropriately expressed in a selected tumour tissue from a patient, 25 We have exploited this techinque to identify antigenic polypeptides expressed by pathogenic organisms during an infection. Autologous antisera produced during the infection is used to screen an expression library created from genomic DNA to identify and clone antigens. 30 5 In its broadest aspect the invention relates to the identification of antigenic polypeptides expressed during an infection by a pathogenic microbe. According to a first aspect of the invention there is provided a method to identify 5 antigenic polypeptides comprising: (i) providing a nucleic acid library encoding genes or partial gene sequences of a pathogenic organism; 10 (ii) transforming/transfecting said library into a host cell; (iii) providing conditions conducive to the expression of said transformed/transfected genes or partial gene sequences; 15 (iv) contacting the polypeptides expressed by the genes/partial gene sequences with autologous antisera derived from an animal infected with, or has been infected with, said pathogenic orgailism; and (v) purifying the nucleic acid encoding the polypeptide or partial polypeptide 20 binding to said autologous antisera. In a preferred method of the invention said library comprises genomic DNA of a pathogenic organism. 25 Ideally said pathogenic organism is bacterial. More preferably still said bacterial organism is selected from the following: Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptoccocus pneumoniae; 30 Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia 6 burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis type B; Shigellaflexneri; Escherichia coli; Haemophilus inftuenzae. Preferably still said pathogenic organism is of the genus Staphylococcus spp. Ideally 5 organism is Staphylococcus aureus or Staphylococcus epidermidis. In a further preferred embodiment of the invention said nucleic acid library is a lambda library, ideally a lambda expression library. 10 According to a second aspect of the invention there is provided a nucleic acid molecule comprising a DNA sequence selected from: (i) the DNA sequence as represented in SEQ ID NO's 1 - 13; 15 (ii) DNA sequences which hybridise to the sequence presented in the SEQ ID No's 1-13 identified in (i) above which encode a polypeptide expressed by a pathogenic organism and (iii) DNA sequences which are degenerate as a result of the genetic code to the 20 DNA sequences defined in (i) and (ii). In a yet still further preferred embodiment of the invention said nucleic acid molecule is genomic DNA. 25 In a preferred embodiment of the invention there is provided an isolated nucleic acid molecule which anneals under stringent hybridisation conditions to the sequences presented in SEQ ID NO's 1- 13. 30 Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1xSSC, 0.1% SDS at 601C. It 7 is well known in the art that optimal hybridisation conditions can be calculated if the sequences of the nucleic acid is known. For example, hybridisation conditions can be determined by the GC content of the nucleic acid subject to hybridisation. Please see Sambrook et al (1989) Molecular Cloning; A Laboratory Approach. A common 5 formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified homology is: Tm= 81.50 C + 16.6 Log [Na] + 0.41[ % G + C] -0.63 (%formamide). 10 According to a third aspect of the invention there is provided at least one polypeptide identified by the method according to the invention. In a preferred embodiment of the invention, said polypeptide is associated with infective pathogenicity of an organism according to any previous aspect or 15 embodiment of the invention. More preferably still said polypeptide is at least one, or part of SEQ ID NO's: 14- 19. According to a fourth aspect of the invention there is provided a nucleic acid 20 molecule characterised in that said nucleic acid molecule is part of a vector adapted to facilitate recombinant expression of the polypeptide encoded by said nucleic acid molecule. In a preferred embodiment of the invention said vector is an expression vector 25 adapted for prokaryotic gene expression. Alternatively said expression vector is adapted for eukaryotic gene expression. Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell 30 specific expression. These promoter sequences may be cell specific, inducible or constitutive. 8 Promoter is an art recognised term and, for the sake of clarity, includes the following features which are provided by example only, and not by way of limitation. Enhancer elements are cis acting nucleic acid sequences often found 5' to the transcription initiation site of a gene ( enhancers can also be found 3' to a gene sequence or even 5 located in intronic sequences and is therefore position independent). Enhancers function to increase the rate of transcription of the gene to which the enhancer is linked. Enhancer activity is responsive to trans acting transcription factors (polypeptides) which have been shown to bind specifically to enhancer elements. The binding/activity of transcription factors (please see Eukaryotic Transcription Factors, 10 by David S Latchman, Academic Press Ltd, San Diego) is responsive to a number of environmental cues which include, by example and not by way of limitation, intermediary metabolites (eg glucose, lipids), environmental effectors ( eg light, heat,). 15 Promoter elements also include so called TATA box and RNA polymerase initiation selection (RIS) sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, inter alia, to facilitate transcription initiation selection by RNA polymerase. 20 Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eulcaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors. 25 Adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination/polyadenylation sequences. This also includes the provision of internal ribosome entry sites (IRES) which function to maximise expression of vector encoded genes arranged in bicistronic or multi-cistronic expression cassettes. 30 9 These adaptations are well known in the art. There is a significant amount of published literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and 5 references therein; Marston, F (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc.(] 994). 10 According to yet a further aspect of the invention there is provided a method for the production of the polypeptides according to any previous aspect or embodiment of the invention comprising: (i) providing a cell transformed/transfected with a vector according to the 15 invention; (ii) growing said cell in conditions conducive to the manufacture of said polypeptides; and 20 (iii) purifying said polypeptide from said cell, or its growth environment. In a preferred method of the invention said vector encodes, and thus said recombinant polypeptide is provided with, a secretion signal to facilitate purification of said polypeptide. 25 According to a fifth aspect of the invention there is provided a cell or cell-line transformed or transfected with the vector according to the invention. In a preferred embodiment of the invention said cell is a prokaryotic cell. 30 Alternatively said cell is a eukaryotic cell selected from: fungal, insect, amphibian; mammalian; plant. 10 According to a yet further aspect of the invention there is provided a vaccine comprising at least one polypeptide according to the invention. 5 Ideally said vaccine further comprises a carrier and/or adjuvant. The terms adjuvant and carrier are construed in the following manner. Some polypeptide or peptide antigens contain B-cell epitopes but no T cell epitopes. Immune responses can be greatly enhanced by the inclusion of. a T cell epitope in the 10 polypeptide/peptide or by the conjugation of the polypeptide/peptide to an immunogenic carrier protein such as key hole limpet haemocyanin or tetanus toxoid which contain multiple T cell epitopes. The conjugate is taken up by antigen presenting cells, processed and presented by human leukocyte antigens (HLA's) class II molecules. This allows T cell help to be given by T cell's specific for carrier 15 derived epitopes to the B cell which is specific for the original antigenic polypeptide/peptide. This can lead to increase in antibody production, secretion and isotype switching. An adjuvant is a substance or procedure which augments specific immune responses 20 to antigens by modulating the activity of immune cells. Examples of adjuvants include, by example only, agonsitic antibodies to co-stimulatory molecules, Freunds adjuvant, muramyl dipeptides, liposomes. An adjuvant is therefore an immunomodulator. A carrier is an immunogenic molecule which, when bound to a second molecule augments immune responses to the latter. 25 In yet a further aspect of the invention there is provided a method to immunise an animal against a pathogenic microbe comprising administering to said animal at least one polypeptide, or part thereof, according to the invention or the vaccine according to the invention. 30 In a preferred method of the invention said animal is human. 11 Preferably the vaccine, or antigenic polypeptide, can be delivered by direct injection either intravenously, intramuscularly, subcutaneously. Further still, the vaccine or antigenic polypeptide, may be taken orally. Preferably the vaccine is against the bacterial species Staphylococcus aureus. 5 The vaccine may also be against the bacterial species Staphylococcus epidermidis. It will also be apparent that vaccines or antigenic polypeptides are effective at preventing or alleviating conditions in animals other than humans, for example and not by way of limitation, family pets, livestock, horses. 10 According to a further aspect of the invention there is provided an antibody, or at least an effective binding part thereof, which binds at least one polypeptide according to the invention. In a preferred embodiment of -the invention said antibody is a polyclonal or monoclonal antibody wherein said antibody is specific to said polypeptide. 15 Alternatively, said antibody is a chimeric antibody produced by recombinant methods to contain the variable region of said antibody with an invariant or constant region of a human antibody. 20 In a further alternative embodiment of the invention, said antibody is humanised by recombinant methods to combine the complimentarity determining regions of said antibody with both the constant (C) regions and the framework regions from the variable (V) regions of a human antibody. Preferably said antibody is provided with a marker including a conventional label or 25 tag, for example a radioactive and/or fluorescent and/or epitope label or tag. Preferably said humanised monoclonal antibody to said polypeptide is produced as a fusion polypeptide in an expression vector suitably adapted for transfection or transformation of prokaryotic or eukaryotic cells. 12 Antibodies, also known as immunoglobulins, are protein molecules which have specificity for foreign molecules (antigens). Immunoglobulins (Ig) are a class of structurally related proteins consisting of two pairs of polypeptide chains, one pair of 5 light (L) (low molecular weight) chain (x or 2,), and one pair of heavy (H) chains (y, a, g, 6 and e), all four linked together by disulphide bonds, Both H and L chains have regions that contribute to the binding of antigen and that are highly variable from one Ig molecule to another. In addition, H and L chains contain regions that are non-variable or constant. 10 The L chains consist of two domains. The carboxy-terminal domain is essentially identical among L chains of a given type and is referred to as the "constant" (C) region. The amino terminal domain varies from L chain to L chain and contributes to the binding site of the antibody. Because of its variability, it is referred to as the 15 "variable" (V) region. The H chains of Ig molecules are of several classes, a, p, a, a, and y (of which there are several sub-classes). An assembled Ig molecule consisting of one or more units of two identical H and L chains, derives its name from the H chain that it possesses. 20 Thus, there are five Ig isotypes: IgA, IgM, IgD, IgE and IgG (with four sub-classes based on the differences in the H chains, i.e., IgGl, IgG2, IgG3 and IgG4). Further detail regarding antibody structure and their various functions can be found in, Using Antibodies: A laboratory manual, Cold Spring Harbour Laboratory Press. 25 Chimeric antibodies are recombinant antibodies in which all of the V-regions of a mouse or rat antibody are combined with human antibody C-regions. Humanised antibodies are recombinant hybrid antibodies which fuse the complimentarity determining regions from a rodent antibody V-region with the framework regions from the human antibody V-regions. The C-regions from the human antibody are also 30 used. The complimentarity determining regions (CDRs) are the regions within the N terminal domain of both the heavy and light chain of the antibody to where the 13 majority of the variation of the V-region is restricted. These regions form loops at the surface of the antibody molecule. These loops provide the binding surface between the antibody and antigen. 5 Antibodies from non-human animals provoke an immune response to the foreign antibody and its removal from the circulation. Both chimeric and humanised antibodies have reduced antigenicity when injected to a human subject because there is a reduced amount of indent (i.e. foreign) antibody within the recombinant hybrid antibody, while the human antibody regions do not illicit an immune response. This 10 results in a weaker immune response and a decrease in the clearance of the antibody. This is clearly desirable when using therapeutic antibodies in the treatment of human diseases. Humanised antibodies are designed to have less "foreign" antibody regions and are therefore thought to be less immunogenic than chimeric antibodies, 15 In another aspect of the invention there is provided a vector which is adapted for the expression of the humanised or chimeric antibodies according to the invention. In a yet further aspect of the invention, there is provided a cell or cell line which has been transformed or transfected with the vector encoding the humanised or chimeric 20 antibody according to the invention. In a yet further aspect of the invention there is provided a method for the production of the humanised or chimeric antibody according to the invention comprising: (i) providing a cell transformed or transfected with a vector which 25 comprises a nucleic acid molecule encoding the humanised or chimeric antibody according to the invention; (ii) growing said cell in conditions conducive to the manufacture of said antibody; and (iii) purifying said antibody from said cell, or its growth environment. 30 14 In a yet further aspect of the invention there is provided a hybridoma cell line which produces a monoclonal antibody as hereinbefore described. In a further aspect of the invention there is provided a method of producing 5 monoclonal antibodies according to the invention using hybridoma cell lines according to the invention. In a further aspect of the invention there is provided a method for preparing a hybridoma cell-line producing monoclonal antibodies according to the invention 10 comprising the steps of: i) immunising an immunocompetent mammal with an immunogen comprising at least one polypeptide having the amino acid sequence as represented in SEQ. ID No 14-19, or fragments thereof; ii) fusing lymphocytes of the immunised immunocompetent mammal 15 with myeloma cells to form hybridoma cells; iii) screening monoclonal antibodies produced by the hybridoma cells of step (ii) for binding activity to the amino acid sequences of(i); iv) culturing the hybridoma cells to proliferate and/or to secrete said monoclonal antibody; and 20 v) recovering the monoclonal antibody from the culture supernatant, Preferably, the said immunocompetent mammal is a mouse. Alternatively, said immunocompetent mammal is a rat. 25 The production of monoclonal antibodies using hybridoma cells is well-known in the art. The methods used to produce monoclonal antibodies are disclosed by Kohler and Milstein in Nature 26 495-497 (1975) and also by Donillard and Hoffman, "Basic Facts about Hybridomas" in Compendium of hImunology V.11 ed, by Schwartz, 1981, which are incorporated by reference. 30 15 In a further aspect of the invention there is provided the use of the antibodies for manufacture of a medicament for the treatment of Staphylococcus aureus-associated septicaemia, food-poisoning or skin disorders. 5 In another aspect of the invention there is provided the use of the antibodies according to the invention for the manufacture of a medicament for the treatment of Staphylococcus epidermidis-associated septicaemia, peritonitis or endocarditis. It will be apparent that the polypeptides identified by the method according to the 10 invention will facilitate the production of therapeutic antibodies to a range of diseases resulting from pathogenic infection, for example, septicaemia; tuberculosis; bacteria-associated food poisoning; blood infections; peritonitis; endocarditis; sepsis; meningitis; pneumonia; stomach ulcers; gonorrhoea; strep throat; streptococcal associated toxic shock; necrotizing fasciitis; impetigo; histoplasmosis; Lyme disease; 15 gastro-enteritis; dysentery; shigellosis. As has already been stated earlier, microbial organisms cause a wide variety of diseases. Listed below, and not by way of limitation, are a number of micro organisms and some of the diseases they cause. 20 Micro-organism Disease(s) caused Staphylococcus aureus Sepsis, food poisoning, septicaemia, Staphylococcus epidermidis Peritonitis, septicaemia, endocarditis, other hospital-associated diseases Enterococcusfaecalis Endocarditis, cystitis, wound infections Mycobacterium tuberculosis Tuberculosis Streptococcus group B Sepsis, meningitis, pneumonia, bladder infections Streptococcus pneumoniae Pneumonia, meningitis Helicobacterpylori Stomach ulcers Neisseria gonorrhoea Gonorrhoea Streptococcus group A Strep throat, necrotizing fasciitis, impetigo, Strep. Toxic shock syndrome Borrella burgdoferi Lyme disease Coccidiodes immitis Pneumonia 16 Histoplasma sapsulatun Histo plasmosis, pneumonia Neisseria meningitidis type B Meningitis Shigellaflexneri Gastro-enteritis, shigellosis, dysentry Escherichia coli Food-poisoning, gastro-enteritis Haemophilus influenzae Meningitis, pneumonia, arthritis, cellulitis An embodiment of the invention will now be described by example only and with 5 reference to the following materials, methods and SEQ ID NO's 1 -19 and Table 1. Materials and Methods A XZAP Express library of genomic DNA of S. aureus 8325/4 was used. It contains 10 fragments of 2-10kb from a partial Sau3A digest of total genomic DNA. This was cloned into the BamH I site of the vector, The library contains >10x coverage of the genome. The library was probed by plaque lift using an initial screen of approximately 20,000 plaque forming units on a 9cm diameter Petri dish. The plating cells used, their treatment, the plating procedure and buffers were exactly as 15 described in the manufacturers handbook (Stratagene). Plating cells, Escherichia coli XL1-Blue MRF', were infected with phage and plated in 3 ml top LB agar containing 10 mM MgSO 4 onto LB plates containing 10 mM MgSO 4 . The plates were then incubated at 42"C for 4 hr. An 8.5cm diameter nitrocellulose filter disc (previously soaked in 10 mM IPTG and air-dried) was placed on each plate and its 20 location marked. The plates were then incubated for a further 3.5 hr at 37 0 C. The filters were removed and washed in TBST buffer before blocking overnight at 4"C in TBST containing 6% w/v dried skimmed milk and 3% v/v pig serum (Sigma). The serum was used to block any Protein A clones on the filter. The filters are then treated with patient serum (1/5000 dilution) in blocking solution for 90 min at room 25 temperature. Antisera have been obtained from patients convalescing from major S. aureus infections. The filters are then washed for 3x10 min in TBST. Secondary antibody used was goat anti-human whole IgG alkaline phosphatase linked (Sigrna) 17 at 1/30,000 dilution in blocking solution at room temperature for 30 min. The filters were then washed as above and developed using a standard colorimetric procedure. Cross-reactive plaques were located on the agar plates and cored into 0.2ml phage 5 buffer with 0.02 ml chloroform. The titre of each core stock was determined and the phage plated at approximately 200 plaques per plate. A plaque lift and screen was performed as above to give single, pure cross-reactive clones, The pure clones were then spotted (1p.l) onto plates to give a confluent plaque of 10 0.5cm diameter. 30 individual clones can be spotted on each plate, A plaque lift is performed and the filter probed with an appropriate sera. In this way clones can be tested for their cross-reactivity with other patient sera, non-infected donor sera and anti-Protein A sera. 15 Individual clones were then excised to give a phagemid in K coli XLOLR using the manufacturers protocol (Stratagene). A plasmid miniprep of each was carried out and the size of the genomic insert determined by restriction mapping. The identity of the cloned insert was determined by DNA sequencing using primers against vector sequence, which allows sequencing across the insert. By comparison of the derived 20 sequence against the public domain databases the nature of the cloned gene(s) can be determined. flybridisation Solutions/Conditions 25 Typically, hybridisation conditions uses 4 - 6 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g NaH 2

PO

4 H20 and 7.4g EDTA dissolved to I litre and the pH adjusted to 7.4); 5-lOx Denhardts solution (50x Denhardts solution contains 5g Ficoll (type 400, Pharmacia), 5g polyvinylpyrrolidone abd 5g bovine serum albumen; 100 g 1.0mg/ml sonicated salmon/herring DNA; 0.1-1.0% sodium dodecyl sulphate; 30 optionally 40-60% deionised formamide. Hybridisation temperature will vary 18 depending on the C2 content of the nucleic acid target sequence but will typically be between 42a- 650 C. 5 10 19 Staphylococcus aureus clones identified in human sera screen TABLE 1 Patient Sera Clone Encoded proteins Locus number A 1 I hemolysin B and C subunit 1 A 3 Atl 2 A 4 y hemolysi B and C subunit 1 A 5 y hernolysin B and C subunit 1 A 7 Novel putative protease (ORF 1 novel 7 antigen like) A 8 Novel nuclease (YisK) 5 A 9 Novel autolysin 6 A 10 y hermolysin B and C subunit 1 A 11 Atl 2 A 14 y hemolysin B and C subunit 1 A 15 y hemolysin B and C subunit 1 A 81 Novel putative protease (ORF 1 novel 7 antigen like) A 85 Novel surface protein 12 A 517 y hemolysin B and C subunit I A 818 Novel putative protease (ORFI novel 7 antigen like) A 519 Novel autolysin 6 A S20 Novel surface protein/toxin 13 A S21 y hemolysin B and C subunit 1 A S25 y hemolysin B and C subunit 1 A S29 Fibrinogen binding protein) 3 A S44 Novel surface protein 12 A 845 Atl 2 A S55 Atl 2 A 564 Atl 2 A S66 Atl 2 B 2 Novel exotoxin (exotoxin 2 like) 8 C 1 Coagulase . 4 C 2 Coagulase 4 C 3. Coagulase 4 C 4 Coagulase 4 C 5 Coagulase 4 C 6 Coagulase 4 C 7 Coagulase 4 C 8 Coagulase 4 C 9 Coagulase 4 C 10 Coagulase 4 20 C 11 Co lase 4 C 13 Coagulase 4 C 14 Coagulase 4 C 15 Coagulase 4 C 19 Coagase 4 C 20 Coagulase 4 C 25 Coagulase 4 E 6 Novel surface proteins 9/10 E 7 Novel surface proteins 9/10 E 11 -y heolysin B and C subunitI F 1 Novel exotoxin (exotoxin 21ike) 8 F 2 Novel exotoxin (exotoxin 2 like) 8 F 3 Novel exotoxin (exoxin 2 like) 8 F 4 Novel exotoxin exotoxin 2 like) 8 F 5 Novel hemolysin (YjfD) 11 21 }|:\qar\IIiterwoveniNRPortb1\DCOAAR\51199816I DOC-2404/2I13 -21A Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. 5 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of 10 endeavour to which this specification relates.

Claims (24)

1. A polypeptide encoded by an isolated nucleic acid molecule comprising a DNA sequence selected from the group consisting of: (i) the DNA sequence as represented in SEQ ID NO:9; (ii) DNA sequences which hybridise under stringent conditions to the sequence presented in the SEQ ID NO:9 identified in (i) above and which encode a polypeptide expressed by a pathogenic organism; and (iii) DNA sequences which are degenerated as a result of the genetic code to the DNA sequences defined in (i) and (ii), for use as a vaccine.

2. A polypeptide having the sequence as represented in SEQ ID NO:20.

3. A vaccine comprising at least one polypeptide according to Claim 1 or 2.

4. A vaccine according to Claim 3 which further comprises a carrier and/or adjuvant.

5. The use of at least one polypeptide, or part thereof, according to Claim I or 2, or a vaccine according to Claim 3 or 4, in the manufacture of a medicament for immunising an animal against a pathogenic microbe.

6. The use according to Claim 5 wherein the animal is human.

7. The use according to Claims 5 or 6 wherein the pathogenic microbe is the bacterial genus Staphylococcus spp.

8. The use according to Claim 7 wherein the pathogenic microbe is the bacterial species Staphylococcus aureus.

9. The use according to Claim 7 wherein the pathogenic microbe is the bacterial H:uar\merwoven\NRPcrtbl\DCCiAAR\5199H16_L DOC-2404/20Dll - 23 species Staphylococcus epidermidis.

10. An antibody, or at least an effective part thereof, which binds at least one polypeptide according to Claim 1 or 2.

11. An antibody according to Claim 10 which is a monoclonal antibody.

12. An antibody according to Claim 10 or 11 wherein said effective part comprises FAb fragments.

13. An antibody according to any of Claims 10 to 12 which is a chimeric antibody.

14. An antibody according to any of Claims 10 to 12 which is a humanised antibody.

15. An antibody according to any of Claims 10 to 14 wherein said antibody is provided with a marker, label or tag.

16. An antibody according to Claim 15 wherein said antibody is provided with a marker selected from a group consisting of: a radioactive label, a fluorescent label; an epitope tag.

17. An antibody according to any of Claims 13 to 16 which is produced as a fusion polypeptide.

18. A vector which is adapted for the expression of antibodies according to any of Claims 13 to 17.

19. A cell which has been transformed or transfected with the vector according to Claim 18. H in vovnNRorth CCAAR592S16_1.DOC-24A4/2013 - 24 20. A method for the production of the antibody according to any of Claims 13 to 17 comprising : (i) providing a cell transformed or transfected with the vector according to Claim 18 and with cell culture conditions; and (ii) purifying said antibody from said cell, or its growth environment.

21. A hybridoma cell line which produces an antibody according to Claim 20.

22. Use of an antibody according to any of Claims 10 to 17 for the manufacture of a medicament for the treatment of Staphylococcus aureus-associated septicaemia, food poisoning or skin disorders.

23. Use of an antibody according to any of Claims 10 to 17 for the manufacture of a medicament for the treatment of Staphylococcus epidermidis-associated septicaemia, peritonitis or endocarditis.

24. A polypeptide according to any one of Claims 1 to 2 or a vaccine according to any one of Claims 3 to 4 or a use of at least one polypeptide according to any one of Claims 5 to 9 or an antibody according to any one of Claims 10 to 17 or a vector according to Claim 18 or a cell according to Claim 19 or a method for the production of the antibody according to Claim 20 or a hybridoma cell line according to Claim 21 or a use of an antibody according to any one of Claims 22 to 23 substantially as hereinbefore described with reference to the Figures and Examples. SEQUENCE LISTING <110> University of Sheffield 5 <120> Antigenic Peptides <130> toxin <140> 10 <141> <160> 32 <170> Patentln Ver. 2.1 15 <210> 1 <211> 2260 <212> DNA <213> Staphylococcus aureus 20 <400> 1 gatcttaatg aaagagtgac tgatgcctta gcaattgcta gttgtatcaa tgcgcatccg 60 tatgtcaaag gagaactttg cgtgtccgat gacttaacgt atacgacagg ttattttgcc 120 25 gctgctaaaa ttggttacca tcgattattt gatattaaac cagttaatac gagatatgga 180 ggcagaataa tatttgtgga cgattgtatt gatttaaatc attacatatc atttttagaa 240 agcacaccga agcaagttgt ttatgaaacg gtataggggt tttagtatga catcaaaaga 30 300 tattactcaa attagtgtca ttgctgcgat tttaaccatt ttggcagttt tgaaaatacc 360 gtccattata ccaggattag attttcaatt atctgcaccg gcagcattat tgatattagc 420 35 tttctttgga attaaaaagt actttttagg tggattatta tctagcctat tattactagt 480 atttggcgta tttaatccaa ttaatgtgat tatctctatt atatttagag ttatagctat 540 tgcagttgtt tatttattga aaataaatgt actatcatta gttttagcaa gtgtattagg 40 600 cagtttggta tataggctac tattatctat tattttaaat ttacctgtgt gggtagtgtt 660 gttaaacgcg attccaggcg taatattcac tttaattgta gctattcctt tatatctcac 720 45 attgagaaaa agaatggcag tattactaag ataataaatc aaaacacggt cgtcacaatt 780 actgttggcg accgtgtttt actagctatt tattgttttc agtttctttt gtatctaaca 840 atttcacttt gtgattttcc caatcaattt catatgttga tttaaatgtt ctagttttaa 50 900 agtttttata atttgcgcct gcccagtaga agccattcca acgaatttgg tataaatcca 960 tttcacgttg ataagttact gtaattttag attttttagc gccatcttgt ctgtgtgata 1020 55 gtacgcttaa aaattctgga ttgaagttac ttctagataa taatggcatt tggtgttgcg 1080 ctatgaagtt ttggccagcg tatgcactgc tttgtctgcc agctaagaag agttcattac 1140 catatgttgg gtggaagcta tctcttccat aaggtcccca accattattc ataattttat 60 1200 gtgcttcaac tccccagcca acatttttat aatttgtgtt gcgacttaat gttgttctgt 1260 1 2013205400 24 Apr 2013 agagatacta atgtcaccac caaatgtata attttgattt tttggtgcat aatcaacgac agatacattg tatttagctc cccaatataa tttcacaaag cctgagttaa tattcccagt acttttatct ttgatgaaat taaatgttaa tgctgtggct gttgttttgt ataaagtaac tgttatttta ccttcagcat tagcagtacc aacggatgat ttgactaatt tattcatttt catgagtctt ccaattgacc tcgtatttca gcctaaagta ttttgaactt gtttactgaa tcattagatt ttttgaaaag tcatagtcat agctttaagt actaaagtat aatctgtgaa attttaaatt tttgtcatcg acttttttta agaaagtaat aataatgcca catatcaatt ctgtcctttc cagtatagtt tctatttaca aactttcttg 1320 ataaaccatt 1380 5 gaaactcttc 1440 gtgagcttat 1500 taggattagg 10 1560 ctttatcata 1620 tatcagaatc 1680 15 cgctgactgg 1740 tagatgtagc 1800 accttgattt 20 1860 aatgcattat 1920 atggcatgag 1980 25 gaaccttttt 2040 ggtggtaact 2100 cctacaaata 30 2160 gctttgacgc 2220 tgttgtgtat 2260 tttataatta attgtttcag aaaaagctgt atttccatta agtccaccag ggactctatg tccgtctaaa taactgttgc cataatgcgt tgatctttta tgacatccat gtttcttccg taagtaattt caaattcgct tgtatcgctt catgagatac tgtggcgata aatgaagggt taaatccact ttgtacaaga cactgtctgg aacgaaataa tctctaggat ctttactatg aggtttgtag aatcgctatc aaaggctgat ttttgacctg attcagtggc gaatgaattc cccataaaac actttttgag ttttgttgtt ctacttcact tacataattt agctaatcga tttagaatag ttaaatgatc 35 <210> 2 <.211> 2902 <212> DNA 40 <213> Staphylococcus aureus <400> 2 gatcgtataa tcgaaacagc accaacggat tacttatctt ggggtgtcgg tgcagtcggt 60 aaccctagat tcatcaatgt tgaaatcgta cacacacacg actatgcttc atttgcacgt 45 120 tcaatgaata actatgctga ctatgcagct acacaattac aatattatgg tttaaaacca 180 gacagtgctg agtatgatgg aaatggtaca gtatggactc actacgctgt aagtaaatat 240 50 ttaggtggta ctgaccatgc cgatccacat ggatatttaa gaagtcataa ttatagttat 300 gatcaattat atgacttaat taatgaaaaa tatttaataa aaatgggtaa agtggcgcca 360 tggggtacgc aatctacaac tacccctact acaccatcaa aaccaacaac accgtcgaaa 55 420 ccatcaactg gtaaattaac agttgctgca aacaatggtg tcgcacaaat caaaccaaca 480 aatagtggtt tatatactac tgtatacgac aaaactggta aagcaactaa tgaagttcaa 540 60 aaaacatttg ctgtatctaa aacagctaca ttaggtaatc aaaaattcta tcttgttcaa 600 gattacaatt ctggtaataa atttggttgg gttaaagaag gcgatgtggt ttacaacaca 660 2 2013205400 24 Apr 2013 gctaaatcac ctgtaaatgt aaatcaatca tattcaatca aacctggtac gaaactttat 720 acagtacctt ggggtacatc taaacaagtt gctggtagtg tgtctggctc tggaaaccaa 780 5 acatttaagg cttcaaagca acaacaaatt gataaatcaa tttatttata tggctctgtg 840 aatggtaaat ctggttgggt aagtaaagca tatttagttg atactgctaa acctacgcct 900 acaccaacac ctaagccatc aacacctaca acaaataata aattaacagt ttcatcatta 10 960 aacggtgttg ctcaaattaa tgctaaaaac aatggcttat tcactacagt ttatgacaaa 1020 actggtaagc caacgaaaga agttcaaaaa acatttgctg taacaaaaga agcaagttta 1080 15 ggtggaaaca aattctactt agttaaagat tacaatagtc caactttaat tggttgggtt 1140 aaacaaggtg acgttattta taacaatgca aaatcacctg taaatgtaat gcaaacatat 1200 acagtaaaac caggt gctaa attatattca gtaccttggg gcacttataa acaagaagct 20 1260 ggtgcagttt ctggtacagg taaccaaact tttaaagcga ctaagcaaca acaaattgat 1320 aaatctatct atttatttgg aactgtaaat ggtaaatctg gttgggtaag taaagcatat 1380 25 ttagctgtac ctgctgcacc taaaaaagca gtagcacaac caaaaacagc tgtaaaagct 1440 tatactgtta ctaaaccaca aacgactcaa acagttagca agattgctca agttaaacca 1500 aacaacactg gtattcgtgc ttctgtttat gaaaaaacag cgaaaaacgg tgcgaaatat 30 1560 gcagaccgta cgttctatgt aacaaaagag cgtgctcatg gtaatgaaac gtatgtatta 1620 ttaaacaata caagccataa catcccatta ggttggttca atgtaaaaga cttaaatgtt 1680 35 caaaacttag gcaaagaagt taaaacgact caaaaatata ctgttaataa atcaaataac 1740 ggcttatcaa tggttccttg gggtactaaa aaccaagtca ttttaacagg caataacatt 1800 gctcaaggta catttaatgc aacgaaacaa gtatctgtag gcaaagatgt ttatttatac 40 1860 ggtactatta ataaccgcac tggttgggta aatgcaaaag atttaactgc accaactgct 1920 gtgaaaccaa ctacatcagc tgccaaagat tataactaca cttatgtaat taaaaatggt 1980 45 aatggttatt actatgtaac accaaattct gatacagcta aatactcatt aaaagcattt 2040 aatgaacaac cattcgcagt tgttaaagaa caagtcatta atggacaaac ttggtactat 2100 ggtaaattat ctaacggtaa attagcatgg attaaatcaa ctgatttagc taaagaatta 50 2160 attaagtata atcaaacagg tatggcatta aaccaagttg ctcaaataca agctggttta 2220 caatataaac cacaagtaca acgtgtacca ggtaagtgga caggtgctaa ctttaatgat 2280 55 gttaagcatg caatggatac gaagcgttta gctcaagatc cagcattaaa atatcaattc 2340 ttacgcttag accaaccaca aaatatttct attgataaaa ttaatcaatt cttaaaaggt 2400 aaaggtgtat tagaaaacca aggtgctgca tttaacaaag ctgctcaaat gtatggcatt 60 2460 aatgaagttt atcttatctc acatgcccta ttagaaacag gtaacggtac ttctcaatta 2520 3 2013205400 24 Apr 2013 gcgaaaggt g cagatgtagt gaacaacaaa gttgtaacta actcaaacac gaaataccat 2580 aacgtatttg gtattgctgc atatgataac gatcctttac gtgaaggtat taaatatgct 264 0 5 aaacaagctg gttgggacac agtatcaaaa gcaatcgttg gtggtgotaa attcatcggc 2700 aactcatatg taaaagctgg tcaaaataca ctttacaaaa tgagatggaa tcctgcacat 2760 ccaggaacac accaatatgc tacagatgta gattgggcta acatcaatgc taaaatcatc 10 2820 aaaggctact atgataaaat tggcgaagtc ggcaaatact tcgacatccc acaatataaa 2880 taagcaacat gaacatagga tc 2902 15 <210> 3 <211> 2792 <212> DNA 20 <213> Staphylococcus aureus <400> 3 gatcaactta atataatgaa ttcggcaaca gaagagcatc atcataaaga ttatattaaa 60 ctatataatt taggtggcgg tgctgctaaa aaaattgcaa tagaggtttt attggggaag 25 120 gataaagtca ttcagaaaaa atacgtgcat attttaccta gtaaagaagg gtacatgtta 180 ccaattaata aaaatgtgta cgaagaatta gaaagaacga ttgagaacaa tggtcatgaa 240 30 gctgatttga atgtacgtat gacttattat cataatgtaa gtcgcaaaca acaggaagtt 300 atattaaaag gtcaaatcga ccgttttaat acttataata ataaagaaat ttatgatttg 360 cagtttatct aaaaattgat ttaagagggt agttgtttat tgcgaaaaat atcattcaat 35 420 tttaatgaaa taatggcgtc attactataa aatattactt tatgttgtaa tgcatttttc 480 tataagatag aactaaaagg aggggcaaag atgcaaatta gacaaataca tcaacatgac 540 40 tttgctcaag tggaccagtt aattagaacg gcatttgaaa atagtgaaca tggttatggt 600 aatgaatcag agctagtaga ccaaattcgt ctaagtgata cgtatgacaa taccttagaa 660 ttagtagctg ttcttcaaaa tgaagttgta gggcacggtt tactaagtga agtttatctt 45 720 gataacgagg cacaacggga aattggatta gtgttagcac ctgtatctgt tgatattcat 780 catcaaaata aaggtattgg gaagcgattg attcaagcat tagaacgaga agcaatatta 840 50 aaaggatata attttatcag tgtattagga tggccgacgt attatgccaa tctaggatat 900 caacgcgcaa gtatgtacga catttatcca ccatatgatg gtataccaga cgaagcgttt 960 ttaattaaag aattaaaagt gaacagttta gcgggaaaaa caggtaccat aaattacaca 55 1020 tctgcttttg aaaaaatatg atttcaagct aggattacat taggtagagt tcatattaat 1080 aataaaaaat gtttgcaatc aaatcgtacg ttgtcgtttg taattcttaa aatagcaata 1140 60 aataaaatgt ttgttagtaa agtattattg tggataataa aatatcgata caaattaatt 1200 gctataatgc aattttagtg tataattcca ttaacagaga ttaaatatat ctttaaaggg 1260 4 2013205400 24 Apr 2013 tatatagtta 1320 agaaaaacac 1380 5 aatcggtttt 1440 atctgatagc 1500 taaaacagac 10 1560 aacgagtgtg 1620 aactacggaa 1680 15 tacaccggca 1740 taatgaaacg 1800 tacaaatgcg 20 1860 caatgaatca 1920 taatacaagt 1980 25 ggcagctggc 2040 tacgactgtg 2100 taattctgct 30 2160 tggtgtaact 2220 tggtgtaatc 2280 35 agatgatgta 2340 gacaggtaat 2400 agtagattat 40 2460 aatcgataaa 2520 cgttattgcg 2580 45 agatcagcaa 2640 aagttacttt 2700 cccaaatcca 50 2760 gtatatagta 2792 atataaaatg actttttaaa aagagggaat aaaatgaata tgaagaaaaa gcaattcgga aaaaatcgat tggcgtggct tcagtgcttg taggtacgtt ggactactca gcagtaaaga agcagatgca agtgaaaata gtgttacgca gcaagtaacg aaagcaaaag taatgattca agtagcgtta gtgctgcacc gacacaaacg tgagtgatac taaaacatcg tcaaacacta ataatggcga gcgcaaaatc cagcacaaca ggaaacgaca caatcatcat caacaaatgc gaaacgccgg taactggtga agctactact acgacaacga atcaagctaa acaactcaat caagcaatac aaatgcggag gaattagtga atcaaacaag acttctaatg atactaatac agtatcatct gtaaattcac ctcaaaattc gaaaatgttt caacaacgca agatacttca actgaagcaa caccttcaaa gctccacaga gtacagatgc aagtaataaa gatgtagtta atcaagcggt gcgcctagaa tgagagcatt tagtttagcg gcagtagctg cagatgcacc acagatatta cgaatcagtt gacgaatgtg acagttggta ttgactctgg tatccgcacc aagcaggtta tgtcaaactg aattatggtt tttcagtgcc gttaaaggtg acacattcaa aataactgta cctaaagaat taaacttaaa tcaactgcta aagtgccacc aattatggct ggagatcaag tattggcaaa gatagtgatg gtaatgttat ttatacattt acagactatg taaatactaa aaagcaactt tgaccatgcc cgcttatatt gaccctgaaa atgttaaaaa gtgacattgg ctactggcat aggtagtaca acagcaaaca aaacagtatt gaaaaatatg gtaagtttta taacttatct attaaaggta caattgacca acaaataata cgtatcgtca gacaatttat gtcaatccaa gtggagataa ccggttttaa caggtaattt aaaaccaaat acggatagta atgcattaat aatacaagta ttaaagtata taaagtagat aatgcagctg atttatctga gtgaatccag aaaactttga ggatgtcact aatagtgtga atattacatt aatcaatata aagtagagtt taatacgcct gatgatcaaa ttacaacacc gttgttaatg gtcatattga tc 55 <210> 4 <211> 2478 <212> DNA <213> Staphylococcus aureus 60 <400> 4 gatcgaattg aacgaagcat ttgcttctca aacgattgca tctattaaag aagtaggtct 60 agatatatca cgtacgaatg tgaatggtgg cgctattgct ttaggtcatc cattaggtgc 120 5 2013205400 24 Apr 2013 tacaggcgca atgttaaccg cgcgtttact taatgaaatg ggtagacgtc ccgatagccg 180 ttacggcatg gttacgatgt gtattggtgt cggcatgggt gcagctgcta tatttgaata 240 5 tgtgcgttag aatggttgat tttggatgaa gcggattcgt tttgttattg aatgaagtag 300 gctgaagttg aagccagttg aagttgaagc gggttgaagc aatttcgttt tattaatgaa 360 10 gctgtgtgaa atatagtgat tgaacaaaaa agtggtttaa tgggatggtg gttatttccg 420 ttttagaatt taacatttac acgtctaatt ttaatcattg ttttaaattt tatgaatcga 480 agccctttga tttaataata tttgctaatg ctagtaactt atctgattgt tcatgtttaa 540 15 aataaagaaa accactcaca tcagtgtgtg ttcgaactag acttgtaagt tccagttcgg 600 cacgactttc taaagcaatt attattgctg tgattgtcgt atatcactta gatgtgcgtg 660 gtttatttta ataggttagt aatatattag gtcatgttat gtttaagact ataatgaata 20 720 aataatttag aaatatgctt ccgattgttc gatgctttaa ttcagttaga agcatcatag 780 aatgcatgat tactgttgta aagatacgta atgttttgta ttgactgtat gtctttggat 840 25 agagttacaa acttattttg ttactctagg cccatatgtc gcagtaccat ctgcatgtgt 900 tgttacattg tatgcatttg ttttacttgg cttcttgtat gtcgggcgag ctccgtatga 960 cacttgaccg tttgcatgtg ttgttacgtt gtatgcattt gttttgcttg gcttgttttg 30 1020 tgttgggcga gcgccatatg atacttggcc gtttccatgt gttgttacgt tatatgcgtt 1080 tgttttgctt ggcttgtttt gtgtcggacg agctccgtat gatacttggc cgtttgcatg 1140 35 tgttgttaca ttgtatgcat tcgtttcgct tggcttcttg tatgtcggac gagctccgta 1200 tgatacttga ccatttgcat gtgttgttac gttatatgca tttgtttctg atggcttatt 1260 gaatcttggt ctcgcttcat atccaaatgt tccatcgttg tattcacgga tacctgtacc 40 1320 agcatctcta tatttaacat atttaggtgt tttgttaaat tgcggtctcg gaccatattg 1380 agaagcttct gttgtttcag ttgcttgagg tttaacttca atatcacttg attctccttg 1440 45 agtacctttt aacgttgatt cagtaccttg tggttttatt tcaagtttag atgagctacc 1500 ttcaagacct tctaaaatag ggttcgttaa cggtgggttt gtataattat tgcttaatga 1560 tgggccgctt tgttccattg ttagaaaatc gggaccttga acgatttcac cttgtaccgt 50 1620 tttattttcc atcgttggat attccggacc ttttacaatt tcacctgtaa ttgtgccctg 1680 tggaatttta actaatggtt gtgcaactgg ttgtgttgtt tcttcagctt taccagccgt 1740 55 agttttaacc tcttgttggt tatcaacttt aggtgcttga ggttcttcaa ctttcttctc 1800 ttcttttact actggcgatt ttgtttcagt ttctccgtat tttttgacag ttttcttttt 1860 ccaagaatca tctgcttctt taactgcttt tttcgtttct tcaactaatt tatcaaaatt 60 1920 aggtttatta tcactatttg ttttatagtt atgtgttgta ggattatatt tcgttataga 1980 6 2013205400 24 Apr 2013 tttcggtcta ttttgtttag tttccataaa gaaatcatca ataattgaat ttaagtcatc 2040 aatcatttct tttttaatac gttcatttgt aattttatgt ggattgtctg tatctccaag 2100 5 gattaagtcc agttttgctc gtaactcttt cgcgtgctcc ccataatcct tatcaccata 2160 atatgataca actaatgtat caatttcaga tacgagatcg tatacttcct tagttgcttt 2220 atcttcttct gctgcattaa aagttttcaa gtctgaattc ttatccttaa tatctttaac 10 2280 ttctctgtga aaatcatcca gtgctctctt taatgcatcc tgtagttcat tgtattcttt 2340 catcgaaagt tcttctaaat tatatttatg aaaattagcc atttttaaat ctgtacgagg 2400 15 attttctttt ttataatttg cataccattg tttataatct tcatattgag atttctttct 2460 ctccaaaaga tattgatc 2478 20 <210> 5 <211> 2070 <212> DNA <213> Staphylococcus aureus 25 <400> 5 tgacgctgct tttgtaaata catataattt ttccacttca tgatttaatt cgttcgcatg 60 atctttgtaa tttctaccaa aagcaatcac attattcgga ggtgttactg gtggtaaaaa 120 30 ttcaatgtca ttaaatgaaa ttttatagtc ttcagctttg ccgctatctt ctgctgctac 180 aactgcttta cgtacttgtt cttgaaaatc taaagtatga ttttgttgta aaccagctaa 240 caatgtttta ggatggaaat ctccttctgc aaagtcagca aatacttgtg ttaaatccca 35 300 tacagcatct tcgcgtttta ctttaacgcc atatgaagtt ttgtcattat acttgaatga 360 taagaatttc attcattctc aactcctcgt ctttatctta attcacatta taactttttt 420 40 cgttatcaaa taacaaataa ataagtaaga caattttgaa aatgagttgt gttcattctg 480 ctacaaggac tttgcactta atcgaaatta ttttttattc ttttgaaaat caaaatacta 540 tagttgcaat gtaccaaatt tgaagaagta taaataacct ttaacttctt tattaagaat 45 600 cgtttgaagc gtattttgat aatatttcat ctgtatctta tatttatttt ttaattgtgt 660 accaatttct tcatctgtca tcccacggcg acgattaaat gcatcggttt tatagtctac 720 50 aaaataatgc acaccatctt taacaaagat taagtcaatc ataccttgaa taattgagac 780 gtcttcgtct ccttgtggca attggtcaac taatgcttgg ttaactacaa acggtaattc 840 acgataaact tgctctgctt cagcaataat cgaatataac tcactattga taaatgtcat 55 900 tatttcatcc atacggatat cttttttcgc atctgcttcg ataatatgtt tatcgattaa 960 tccatcgata tactgatgta actcaacttc agatatgcgt tcttttttga atggtaaatg 1020 60 ttgcatcact gtatgcatta acgtaccaat ttcattcgct tttcgtttac cttgttcact 1080 tagaaattta ggtcgttcat acgttgaaaa accgatacga tattgcctta ctcgttcgta 1140 7 2013205400 24 Apr 2013 tcagaaacag attgttttga agttggtgtt taatttgtgc ttaaccgaac gatattcatc acttgtgcca 1200 gggcttttta 1260 5 tttaacatct 1320 attatctaaa 1380 cggacgacta 10 1440. tgacgcagat 1500 taatcgttca 1560 15 tgatttatca 1620 tacatagact 1680 aaccgaagct 20 1740 accaaattgc 1800 caatccagaa 1860 25 tctaacgaca 1920 aatcaattca 1980 ctcgatagct 30 2040 tccactaaag 2070 ctttcttctg gtatcattta tcattaccat atggtttctg ctatcttcaa tgatttaaaa taaatgacaa tcgataaaac ttattaaata tttcatattg catatggata tttgcatagt tagacacatc tttgtgctat tcttttcaat tcgataatca ttctaattga ttcaaagtac atctttttca ataaataaga agaaatagac ataaagttgt aagttctttt tttatccaca acaattgaaa aattttaaat tggaacggat aattgctcta tctttcgctc tcggcaacag tcaaaataat cgtttattaa ctactatgaa ccaaaatctt ctaaaacttg cgtccacgtc tatttacatt catctggaat ttggtgaagt gttctagtaa ttgttaatgc ctctatatgc ccattccgag aatcttttga ttgtcatcat tgcctctttc aattctcaaa caccaataag tgatgtttag ataaaatact ttgacagcaa tgtgctcacc tttttcactc taccaattaa aatcgcattt cttctgacac aaagatggaa atgccatttc tattgaataa cataatgatc taactggttg tttcaaatca atggaaactc tagaccttta ttatcgtttg gaccaactac attttcctca gaataaattg atataaacct aaccataaag atttgcacgt 35 <210> 6 <211> 2394 <212> DNA <213> Staphylococcus aureus 40 <400> 6 gatcagattt attagacagt attccagata tacccacacc aaagccagaa aagacgttaa 60 cacttggtaa aggtaatgga ttgttaagtg gattattaaa tgctgatggt aatgtatctt 120 tgcctaaagc gggggaaacg ataaaagaac attggttgcc gatatctgta attgttggtg 45 180 caatgggtgt actaatgatt tggttatcac gacgcaataa gttgaaaaat aaagcataat 240 tatattgggg gaagagcatc tatatatttt tttaagtata taagacgtct tatttcccct 300 50 taatttattg tgaagtatat gcaaaatgca atgaatagat tgtccatcat tttaacgtta 360 taatgaattt aacgacttag aactacacaa gtaaaggaga atgaagatgt ctcgaaaaac 420 ggcgctatta gttttggata tgcaagaagg tatagcgagt agtgtaccta gaataaaaaa 55 480 tattattaaa gcgaatcaga gagcaattga agcagcaaga caacatcgaa taccagtcat 540 tttcatacgt ttagtgttag ataagcattt taatgatgtc tcctcgagta ataaagtgtt 600 60 ttcaacaatt aaagctcaag gatatgcgat tactgaagca gatgcatcta cacgaatact 660 tgaagattta gcaccactag aagatgagcc gattatttct aagcgacgct ttagcgcatt 720 8 2013205400 24 Apr 2013 tacaggtagt tacttggaag tttatttacg tgcaaatgat attaatcatt tagtattaac 780 gggtgtctct acaagtggag ctgtattgag cacggcatta gaaagtgtag ataaagacta 840 5 ttatattact gttttagaag atgctgttgg tgatagatca gatgataaac atgactttat 900 tattgaacaa attttatcac gctcatgtga cattgaatcc gtagagtcat ggaaaagtag 960 tttatagtta atataacgtc aattaaagct cggcagtaat gtttgagaat aagtacattt 10 1020 gctcatattt ataaaatgtg tgagatggca attgaaacgg atatgatgag gaacatttga 1080 acataaaata atatatttat ataaaacgac ccgaggcgtt cgaactgaat gcctcgggtt 1140 15 taattgaata agaaatcgga cttatgaaca gaaatatgtt taagtccgaa ctccttgttt 1200 atacttataa attttacggg tttaatataa tacttattta cctgtaatat atgataattc 1260 ttcagcggca gctgcgttga tagttctatg agaaatgata cctaatcctt taacattgga 20 1320 ttctgaaata acgatagaac catcactgtt aactttttca acaaatgcta catgaccgta 1380 atgttgatct gcaccaaatt gtccagcctc aaatacaaca gcagcatgac gttttggtgt 1440 25 atgacttact tgataatcac ggtattgagc tcgattattc caattatgtg catcacctaa 1500 atcacctgag atagatgtac caaattgttt catacggtta tatacgtacc aagtacattg 1560 gccatgtgga tatggcatac tatcagatac ctcacggaaa ggtttgaatt catctgatga 30 1620 atcatcataa tccttgatag aacgttcata tttatctaaa tctggcatgc gttcatcgtc 1680 aaactgagtt aattgatagt gtttaataat actgtttaat ttcttagcat agtttggatc 1740 35 tgtagcatat gttttagata agtgtgatgt tgcatcttta taagaatcgg cttccgattt 1800 ccatgttggt ttataaattg ttcgattgcc atcaatacca tttttaataa ggtcagagta 1860 atcttttagt gattctttcg tgcttggata ttttcggaat ccagcattaa tactatacaa 40 1920 ttgattacca tcagcttcta atgtgttaaa aggaacagaa ttcccttcaa aagcaccttt 1980 gataccgaat aaattatggt ttggtgactt agctaaagca ctacgacctg agtcagattc 2040 45 taagattgct tgggcaatca tgacagacgc ataaatatcg ttatcttgac caatgcgatg 2100 tgcatcttta gcaattgatt tgacaaattg acgtgtatct tttgagtcaa caacgttaaa 2160 ttgtccgcta tcatcattgt tagatatact aggatctgtt tcgaataatg atgttgcacg 50 2220 tgtatccttt tgattaacat cgttattgaa tgattgagca ggtttagatt tatgtttcaa 2280 ttcatcttgt gttggtaact gtggattctt tgtattagat ttttcatttt tgtctttttt 2340 55 agattgagat gcataatctt tttgtgtttt ctttgcatct tcactgtatt gatc 2394 <210> 7 60 <211> 2033 <212> DNA <213> Staphylococcus aureus 9 2013205400 24 Apr 2013 <400> 7 gatctggaac caggtatgga 120 5 gattttataa agttaaaaaa 180 atgtggaaga taaagctgtt 240 taaaaatagc atcagaagct 10 300 catatataaa 360 acatgattat 420 15 gtaaatacga 480 aaggatatgg 540 aataaatcct 20 600 catctctgtg 660 attataatta 720 25 gtattgcagc 780 gtattcaaca aacagccaaa gccgaaaata ctgttaaaca 840 caccatacag tggtgttaca tggatgggcg ctggaacagg 30 900 caatcattac caataaacat gttacctatc acatgaaagt 960 atcctaatgg tttttataat 1020 35 atcctggtaa agaagatatt 1080 gtagaaaatt caaagatttc 1140 aacctatatc agtcattggt 40 1200 caactggtaa agtattatca 1260 ctggtagctc tggttcacct 1320 45 ccggtaataa gccatcaggt 1380 ttaagaaatt cattgcagat 1440 ctgacaaaat atactataac 50 1500 aaagcceatc aacgattgat 1560 aatgaacaac tttttgacat 1620 55 caacatttct ataaaatttt 1680 ccaacatcca aattatcaac 1740 aagagataaa ttacttatgc 60 1800 tcagcaacaa gctgaattac 1860 aggtttcatt gtcggtaaaa atacaattgt taccaacaag catgtcgttg 60 aattggtgca catattatag cgcatcccaa tggtgaatat aataatggcg attgtccgtt attcaggtca agaagatatt gccattctac catccaaaaa acaggaattt taaagattac acaggcattt aaagaaaatg aacgcatttc aattgttggc tatccaaatc taaatttcaa atgtatgagt caacaggaaa agtgctgtca gttaaaggca tactgatgct ttcgtagaac caggcaactc aggttcagct gtatttaaca agttgtaggt gttcactttg gtggaaacgg ccctggaaat aaaagtacaa tgtttatttc tctcctgaaa ttaagaaatt cattgcagat aacacagata tacatagata aatgatttta aaaattaaca acaaactcaa caattcaaat attccattta ttcgaaatga ttaaaaaaaa taaaacttca aaaagctaac tacaaatact tagaggagca gaaaaatgaa taaaaatata atcatcaaaa attgacgatt ttaacatcaa taactggtgt cggcacaaca atggttgaag aattacaaat acaaatgttg atttgtagtt ggaaatcata cggtgatgaa atcaaagcac aacggtggtg gactttataa gcggttgtac aagttgaaga actagtaaat ttaatatagc tatccaaatc ctaatggaaa gtgaatggga atatagtgtc atattaaata gtaaacacga gaaagcacaa gaggatttgc aatttagata aataattaaa acttagacat tcacccaatc taacatttat taatatatat tgcattattt aatatgcatc tttcaccaac tcaattgttg attggtttta tttatgtatg cattaagaat ataaatgatt ttgaaagcat ttgaaagcta tcaataacaa ttgcgccact aaaactcaaa atttccacca atcgcaacat aaccaaatgt tataataaat ctattacaca aaaggcggag gaatcacatg tctattactg aaaaacaacg ataaaaaatt atggtcgatt gcgaatgatt taagagggaa agttactaag attgtagatt aaaatcaaca caaccaaaag atcagaagct aaagaaaatg taaactacaa atgtatgaat ttcggatgca attattcagc agctattggt gtaatctatg tgtttatttc tctcctgaaa 10 2013205400 24 Apr 2013 catggatgcg agtgaattcc gtaattacat tttaggcttg attttctatc gcttcttatc 1920 tgaaaaagcc gaacaagaat atqcagatgc cttgtcaggt gaagacatca cgtatcaaga 1980 5 agcatgggca gatgaagaat atcgtgaaga cttaaaagca gaattaattg atc 2033 <210> 8 10 <211> 2794 <212> DNA <213> Staphylococcus aureus <400> 8 15 gatcaaacgt tgcttaactt ctttttaatg cttaaaaatt atttcaaagg cacatagaaa 60 cgctatatta atctcatact cactcattat tttttgct.ta aattacttaa taatacttca 120 ataattgtta aaaggggttt aatgtgatta tcttagaacg ccatctataa tgatgttgta 180 20 tgattcaaat tacgtaaaaa gacaatcgaa tataatatag attggagcat acaattatga 240 aaatgagaac aattgctaaa accagtttag cactagggct tttaacaaca ggcgcaatta 300 cagtaacgac gcaatcggtc aaagcagaaa aaatacaatc aactaaagtt gacaaagtac 25 360 caacgcttaa agcagagcga ttagcaatga taaacataac agcaggtgca aattcagcga 420 caacacaagc agctaacaca agacaagaac gcacgcctaa actcgaaaag gcaccaaata 480 30 ctaatgagga aaaaacctca gcttccaaa .a tagaaaaaat atcacaacct aaacaagaag 540 agcagaaaac gcttaatata tcagcaacgc cagcgcctaa acaagaacaa tcacaaacga 6D0 caaccgaatc cacaacgccg aaaactaaag tgacaacacc tccatcaaca aacacgccac 35 660 aaccaatgca atctactaaa tcagacacac cacaatctcc aaccataaaa caagcacaaa 720 cagatatgac tcctaaatat gaagatttaa gagcgtatta tacaaaaccg agttttgaat 780 40 ttgaaaagca gtttggattt atgctcaaac catggacgac ggttaggttt atgaatgtta 840 ttccaaatag gttcatctat aaaatagctt tagttggaaa agatgagaaa aaatataaag 900 atggacctta cgataatatc gatgtattta tcgttttaga agacaataaa tatcaattga 45 960 aaaaatattc tgtcggtggc atcacgaaga ctaatagtaa aaaagttaat cacaaagtag 1020 aattaagcat tactaaaaaa gataatcaag gtatgatttc acgcgatgtt tcagaataca 1080 50 tgattactaa ggaagagatt tccttgaaag agcttgattt taaattgaga aaacaactta 1140 ttgaaaaaca taatctttac ggtaacatgg gttcaggaac aatcgttatt aaaatgaaaa 1200 acggtgggaa atatacgttt gaattacaca aaaaactgca agagcatcgt atggcagacg 55 1260 tcatagatgg cactaatatt gataacattg aagtgaatat aaaataatca tgacattctc 1320 taaatagaag ctgtcatcgg aaaaacaaga agttaagtga caacggttta catgttgctt 1380 60 agcttctttt attatgcgta atgatgtaaa aagacgaata ttcatttgtt tgtaaaagtg 1440 gcatttctat gtcttaaaag tgacgaaact tcaaatgtgc caagtgttga atcacatcaa 1500 11 2013205400 24 Apr 2013 aatcattttt atttaacgaa cattatggat ttcttaattt acttaacgat gattcaaata 1560 tagttaaaca aggtttaatg tgaatggagc aatacgccat ctataataaa gctgtatgat 1620 5 tcaatgaatg taatcgaaca aatctaataa ttacgaatgg agcatacaac tatgaaaata 1680 acaacgattg ctaaaacaag tttagcacta ggccttttaa caacaggtgt aatcacaacg 1740 acaacgcaag cagcaaacgc gacaacacta tcttccacta aagtggaagc accacaatca 10 1800 acaccgccct caactaaaat agaagcaccg caatcaaaac caaacgcgac aacaccgccc 1860 tcaactaaag tagaagcacc gcaacaaaca gcaaatgcga caacaccgcc ttcaactaaa 1920 15 gtgacaacac ctccatcaac aaacacgcca caaccaatgc aatctactaa atcagacaca 1980 ccacaatcgc caaccacaaa acaagtacca acagaaataa atcctaaatt taaagattta 2040 agagcgtatt atacgaaacc aagtttagaa tttaaaaatg agattggtat tattttaaaa 20 2100 aaatggacga caataagatt tatgaatgtt gtcccagatt atttcatata taaaattgct 2160 ttagttggta aagatgataa aaaatatggt gaaggagtac ataggaatgt cgatgtattt 2220 25 gtcgttttag aagaaaataa ttacaatctg gaaaaatatt ctgtcggtgg tatcacaaag 2280 agtaatagta aaaaagttga tcacaaagca ggagtaagaa ttactaagga agataataaa 2340 ggtacaatct ctcatgatgt ttcagaattc aagattacta aagaacagat ttccttgaaa 30 2400 gaacttgatt ttaaattgag aaaacaactt attgaaaaaa ataatctgta cggtaacgtt 2460 ggttcaggta aaattgttat taaaatgaaa aacggtggaa agtacacgtt tgaattgcac 2520 35 aaaaaattac aagaaaatcg catggcagat gtcatagatg gcactaatat tgataacatt 2580 gaagtgaata taaaataatc atgacattct ctaaatagaa gctgtcatcg gaaaaacaag 2640 aagttaagtg acaacggcct acatgttgct tagcttcttt tgttatgttc gatgatttga 40 2700 gaacccgaat tttcgatggg tccaaatatg acgtggaaga gacctgaatt tatctgtaaa 2760 tccctatcta tcgggtgtga agcacaacgg gatc 2794 45 <210> 9 <211> 505 <212> DNA 50 <213> Staphylococcus aureus. <400> 9 gatcatagcg caccaaactc tcgtccaatt gattttgaaa tgaaaaagaa agatggaact 60 caacagtttt atcattatgc aagttctgtt aaacctgcta gagttatttt cactgattca 55 120 aaaccagaaa ttgaattagg attacaatca ggtcaatttt ggagaaaatt tgaagtttat 180 gaaggtgaca aaaagttgcc aattaaatta gtatcatacg atactgttaa agattatgct 240 60 tacattcgct tctctgtatc aaacggaaca aaagctgtta aaattgttag ttcaacacac 300 ttcaataaca aagaagaaaa atacgattac acattaatgg aattcgcaca accaatttat 360 12 2013205400 24 Apr 2013 aacagtgcag ataaattcaa aactgaagaa gattataaag ctgaaaaatt attagcgcca 420 tataaaaaag cgaaaacact agaaagacaa gtttatgaat taaataaaat tcaagataaa 480 5 cttcctgaaa aattaaaggc tgagt 505 <210> 10 10 <211> 673 <212> DNA <213> Staphylococcus aureus <400> 10 15 gatcaaacta aaacacaaac tgctcataca gttaaaacag cacaaactgc tcaagaacaa 60 aataaagttc aaacacctgt taaagatgtt gcaacagcga aatctgaaag caacaatcaa 120 gctgtaagtg ataataaatc acaacaaact aacaaagtta caaaacataa cgaaacgcct 180 20 aaacaagcat ctaaagctaa agaattacca aaaactggtt taacttcagt tgataacttt 240 attagcacag ttgccttcgc aacacttgcc cttttaggtt cattatcttt attacttttc 300 aaaagaaaag aatctaaata aatcatcgtc acactcataa cttaatatat tttttatttt 25 360 aaattttatt taacctatgt catagatatt tcataatcta taacataggt'tatttttttt 420 ataaaataac gttgcaatta actaacattt caatgtcaat acaagtaatc aattgataat 480 30 gattatcagt tgataatata caattaggag ttgtttctac aacatgaaca aacagcaaaa 540 agaatttaaa tcattttatt caattagaaa gtcatcacta ggcgtgcatc tgtagcaatt 600 agtacacttt tattattaat gtcaaatggc gaagcacaag ccagcagctt gaagaaaaca 35 660 ggtggtccaa ttc 673 40 <210> 11 <211> 2238 <212> DNA <213> Staphylococcus aureus 45 <400> 11 gatcttcagc ttgatgtttt cgtttgatta aattggtaaa atagaaacgc aatccacaaa 60 aatggcaagc actaaaataa tgtttggggg tgcttgtgct tttgtggatt gcggtcgatt 120 atttatattg catgatttga ttaatttgat tgattatatt ggacatgatg gtgttggcgg 50 180 gatgcgttgt tgctagtogc gggctttgtc cactccacat atgtattaac tctttgtcgc 240 cgatgtttgc tgcggctttt cttatgctac ttgttagctc attttgtatt ggataatctg 300 55 ggatatcgcc ttcgtattgg gacatttctt cgataaacct attgttgata ccgcgtgcaa 360 gctttccact aaacgctttt gtaatgactg tatctgtttc tttactattt ataattgcat 420 60 ct 8 cgcagtag ttctgatgca ttactgtctt gtgatgttaa aaatgcggtg cccatttgta 40 ccccttctgc acctaagaca atacttgcca aaactcctct accatccata attccaccag 540 13 2013205400 24 Apr 2013 cggcaatgac cggaattgaa acgacatcta caatttgtgg cactaaagat attgttccaa 600 ccataggtaa ttgattttta ggttttaaaa atgaaccacg atgtccacct gcttcactac 660 5 cttgagcaac gatagcatcc atacccgctt tttcattcgc aatagcttca tcaacacttg 720 ' ttgctgtacc tataagtttg acattcgctg ctttcaacct gcttataatc tgttcgcttg 780 gaattccaaa agtaaaacaa catacaggca cttgcttttt aattatcgta tcaatatgac 10 840 acttaaattg ttgttcttcg gtaattttta caaccggctc ttctaaatgt aatgcgcgtc 900 gataaggttt taaccatgca ttcatatttt caatttgact actggtatat gattgttgac 960 15 ttggtacaaa gacatttacg ccaaaagaat ttgacgttaa ttggcgtaca taatctattt 1020 catcttccaa ttgctgcgta ttaaagtaac ctgcgcctat tgtgcctaac ccaccactgt 1080 tacttactga tgcaactaat ttcggtgtcg tacttcctgc catacctgct tgtataattg 20 1140 gatattcaat acttaacatt tgagtaagtc gattcttatt ccacatagct gttcgctcct 1200 tatatagata cgttgcgatt tttccgttgt tgaaattgaa tttgctgttg agaaagtttt 1260 25 tctttttcct ttttatccat ctcatcttca atttccatac ctaataattc ttcaattaag 1320 tcttcatgtg acactatcgc ttcagtacca ccaaattcgt ccaacacaat tgctaaatgt 1380 tttctagaaa tagtcatctt acgtaatacc cattcagctt tattgtgttc attcacaaat 30 1440 aatggcttag ctgaatagtt tgtaatttga ttttcttttt tattactcca agccaacaga 1500 tatttagaat gaaacacccc aataatgtta tcaatatctc cctcgtacac tggatatcta 1560 35 gtgtatggct tattcataac cgtttcataa acttcttcgt atgtcgcatt tgaagcaaat 1620 gccgtcacat taattctagg tgttgtatct acatctttta cttttaaatt ttcaaaatta 1680 atgacacctt ccaacctact cgtctcaatt tcatttaaag caccttcatg tccagcaatt 40 1740 gctaacattg ttttaaattc ttcttttgaa aattgatgtt cttgaggttg gcccttagat 1800 aaacttcgat taatactgtc cgtcaactta tttaaaagta atgtgatagg acggaacaca 1860 45 atgacacaaa tattaataat tggatataca agccttgtta ttttatctgg aaatgttgca 1920 gcgacagact tgggaatcac ttcggagatc aaaatgataa caactgttaa aacagctgat 1980 gcaataccaa cgctaatccc ccaacgtaaa gccataattg taacaagtgt tggtaataaa 50 2040 atattcgcga cattattccc aattagaatc gttgtaataa actcacttgg tttttcaagt 2100 aactttacaa tgccttttgc ttttttatca cctttgtcag cttcagtttt aaattttgct 2160 55 ttattggcag ccgttaatgc cgtctcgctt cctgaaaaga aaaacgaaat aaatatcaat 2220 ataattatgg caatgatc 2238 60 <210> 12 <211> 7975 <212> DNA 14 2013205400 24 Apr 2013 <213> Staphylococcus aureus <400> 12 gatcaaacga caattattaa ttcgttaacg tttactgaaa cagtaccaaa tagaagttat 60 5 gcaagagcaa gtgcgaatga aatcactagt aaaacagtta gtaatgtcag tcgtactgga 120 aataatgcca atgtcacagt aactgttact tatcaagatg gaacaacatc aacagtgact 180 gtacctgtaa agcatgtcat tccagaaatc gttgcacatt cgcattacac tgtacaaggc 10 240 caagacttcc cagcaggtaa tggttctagt gcatcagatt actttaagtt atctaatggt 300 agtgacattg cagatgcaac tattacatgg gtaagtggac aagcgccaaa taaagataat 360 15 acacgtattg gtgaagatat aactgtaact gcacatatct taattgatgg cgaaacaacg 420 ccgattacga aaacagcaac atataaagta gtaagaactg taccgaaaca tgtctttgaa 980 acagccagag gtgttttata cccaggtgtt tcagatatgt atgatgcgaa acaatatgtt 20 540 aagccagtaa ataattcttg gtcgacaaat gcgcaacata tgaatttcca atttgttgga 600 acatatggtc ctaacaaaga tgttgtaggc atatctactc gtcttattag agtgacatat 660 25 gataatagac aaacagaaga tttaactatt ttatctaaag ttaaacctga cccacctaga 720 attgacgcaa actctgtgac atataaagca ggtcttacaa accaagaaat taaagttaat 780 aacgtattaa ataactcgtc agtaaaatta tttaaagcag ataatacacc attaaatgtc 30 840 acaaatatta ctcatggtag cggttttagt tcggttgtga cagtaagtga cgcgttacca 900 aatggcggaa ttaaagcaaa atcttcaatt tcaatgaaca atgtgacgta tacgacgcaa 960 35 gacgaacatg gtcaagttgt tacagtaaca agaaatgaat ctgttgattc aaatgacagt 1020 gcaacagtaa cagtgacacc acaattacaa gcaactactg aaggcgctgt atttattaaa 1080 ggtggcgacg gttttgattt cggacacgta gaaagattta ttcaaaaccc gccacatggg 40 1140 gcaacggttg catggcatga tagtccagat acatggaaga atacagtcgg taacactcat 1200 aaaactgcgg ttgtaacatt acctaatggt caaggtacgc gtaatgttga agttccagtc 1260 45 aaagtttatc cagttgctaa tgcaaaggcg ccatcacgtg atgtgaaagg tcaaaatttg 1320 actaatggaa cggatgcgat gaactacatt acatttgatc caaatacaaa cacaaatggt 1380 atcactgcag catgggcaaa tagacaacaa ccaaataacc aacaagcagg cgtgcaacat 50 1440 ttaaatgtcg atgtcacata tccaggtatt tcagctgcta aacgagttcc tgttactgtt 1500 aatgtatatc aatttgaatt ccctcaaact acttatacga caacggttgg aggcacttta 1560 55 gcaagtggta cgcaagcatc aggatatgca catatgcaaa atgctactgg tttaccaaca 1620 gatggattta cgtataaatg gaatcgtgat actacaggta caaatgacgc aaactggtca 1680 60 1 gct 790 atgaata aaccgaatgt ggctaaagtc gttaacgcaa aatatgacgt catctataac ggacatactt ttgcaacatc tttaccagcg aaatttgtag taaaagatgt gcaaccagcg 1800 15 2013205400 24 Apr 2013 caactgtagc aggtattgct ggaactaata atggtattac tgttgcagca accctgctga tacaattcaa gttgttgcaa cgcaaggaag cggagagaca agcaacgtag tgatgatttc acagttgtcg caccacaacc gaaccaagcg tttggcaaaa tggtcatatt gatatcacgc ctaataatcc atcaggacat caactcaagc aatggatatt gcttacactg aaaaagtggg taatggtgca agacaattaa tgttgttcgt ggtcaaaata atcaatggac aattgcgaat atgtaacgtt agatgcacaa actggtaaag tgacgttcaa tgccaatact attcatcaat gtacattaac gttcaaatgt caacgattaa ttcctgtgac cacaattact tgcaccggca aacagcagct aaatggcaca agtaacttac ccgaaagcag gtacaggtca gctcatactg tcaacacaac gaaattaaca atgcagttca gcaatgccta ctaatttagc aatgatggta gtactgaaga ctcagtaagt tgaaattgtg agttgctaat tggtggtagc agtacaagag caaaagcgga taaacgtgag ttaatcacag ctaaaaatca tttagatgat ctgaaggtaa aaagccaggt acaattacgc agtacaataa tgcaatgcat aacaaatcaa tactgcgaaa acagaagcac aacaagtgat taataatgag cacaacaagt ttctgacgca ctaactaaag ttcgtgcagc acaaactaag ctaaagcatt acttcaaaat aaagaagata atagccaatt agtaacgtct tacaaagttc tgtgaaccaa gtaccatcaa ctgctggtat gacgcaacaa actataatgc gaagaagcgt gaagcagaaa ctgaaataac tgcagctcaa acaatggcga tgcaactgca caacaaattt cagatgaaaa acatcgtgtc taacagcatt aaaccaagcg aaacatgatt taactgcaga tacacatgcc cagtgcaaca attgaatcgc acaggtacaa cgactggtaa gaagccggca cttacaataa ttcgattcgt gcacttcaaa gtgacttaac aagtgctaaa atgctattat tcaaaagcca ataagaacag tacaagaagt gcaatctgcg taaatcgtgt caatgagcga ttaacgcaag atagtgcttt aaaaactgct aagacgaaac ctgatggtat gacacaatca tcaatccaag caattaatca ttgatgaaga catatgaaaa attagtacct aatcaataaa tgctaaacgt cagaatcaac aaatgcacaa aatgttatta acaatggtga tgcgactgac aaaccaactg tgactgaaac agcggcagga gcgattacaa ttgcacctgg agcaaaccaa 1660 acagtgaata cacatgccgg taacgtaacg acatacgctg ataaattagt tattaaacgt 1920 5 aatggtaacg ttgtgacgac atttacacgt cgcaataata cgagtccatg ggtgaaagaa 1980 gcatctgcag 2040 ggtactttca 10 2100 gtgagtgatg 2160 actactaaga 2220 15 ttaattaatc 2280 gaacatagta 2340 aagcctgact 20 2400 ataaaaccaa 2460 agtaatccaa 2520 25 aaagattatg 2580 aaacgtactg 2640 acaacgacga 30 2700 tccattttca 2760 ccagtaagca 2820 35 aatgcgcaac 2880 cgtgcaacac 2940 attgatcaag 40 3000 aaaaataact 3060 agtattgata 3120 45 cgtgttattg 3180 gat aacgcat 3240 ttagagcaag 50 3300 agtattactg 3360 aatagcgcta 3420 55 ttaacaaatg 3480 ttagctgata 354 0 tcagtaacta 60 3600 gcgggtcaaa 3660 16 2013205400 24 Apr 2013 caacaaattg ccgcagaaaa aacaaaagta gaagaaaaat ataatagctt aaaacaagca 3720 attgctggat taactccaga cttggcacca ttacaaactg caaaaactca gttgcaaaat 3780 5 gatattgatc agccaacgag tacgactggt atgacaagcg catctattgc agcatttaat 3840 gaaaaacttt cagcagctag aactaaaatt caagaaattg atcgtgtatt agcctcacat 3900 ccagatgttg cgacaatacg tcaaaacgtg acagcagcga atgccgctaa atcagcactt 10 3960 gatcaagcac gtaatggctt aacagtcgat aaagcgcctt tagaaaatgc gaaaaatcaa 4020 ctacaatata gtattgacac gcaaacaagt acaactggta tgacacaaga ctctataaat 4080 15 gcatacaatg cgaagttaac agctgcacgt aataagattc aacaaatcaa tcaagtatta 4140 gcaggttcac cgactgtaga acaaattaat acaaatacgt ctacagcaaa tcaagctaaa 9200 tctgatttag atcatgcacg tcaagcttta acaccagata aagcgccgct tcaaactgcg 20 4260 aaaacgcaat tagaacaaag cattaatcaa ccaacggata caacaggtat gacgaccgct 4320 tcgttaaatg cgtacaacca aaaattacaa gcagcgcgtc aaaagttaac tgaaattaat 4380 25 caagtgttga atggcaaccc aactgtccaa aatatcaatg ataaagtgac agaggcaaac 4440 caagctaagg atcaattaaa tacagcacgt caaggtttaa cattagatag acagccagcg 4500 ttaacaacat tacatggtgc atctaactta aaccaagcac aacaaaataa tttcacgcaa 30 4560 caaattaatg ctgctcaaaa tcatgctgcg cttgaaacaa ttaagtctaa cattacggct 9620 ttaaatactg cgatgacgaa attaaaagac agtgttgcgg ataataatac aattaaatca 4680 35 gatcaaaatt acactgacgc aacaccagct aataaacaag cgtatgataa tgcagttaat 4740 gcggctaaag gtgtcattgg agaaacgact aatccaacga tggatgttaa cacagtgaac 4800 caaaaagcag catctgttaa atcgacgaaa gatgctttag atggtcaaca aaacttacaa 40 4860 cgtgcgaaaa cagaagcaac aaatgcgatt acgcatgcaa gtgatttaaa ccaagcacaa 4920 aagaatgcat . taacacaaca agtgaatagt gcacaaaacg tgcaagcagt aaatgatatt 4980 45 aaacaaacga ctcaaagctt aaatactgct atgacaggtt taaaacgtgg cgttgctaat 5040 cataaccaag tcgtacaaag tgataattat gtcaacgcag atactaataa gaaaaatgat 5100 tacaacaatg catacaacca tgcgaatgac attattaatg gtaatgcaca acatccagtt 50 516D ataacaccaa gtgatgttaa caatgcttta tcaaatgtca caagtaaaga acatgcattg 5220 aatggtgaag ctaagttaaa tgctgcgaaa caagaagcga atactgcatt aggtcattta 5280 55 aacaatttaa ataatgcaca acgtcaaaac ttacaatcgc aaattaatgg tgcgcatcaa 5340 attgatgcag ttaatacaat taagcaaaat gcaacaaact tgaatagtgc aatgggtaac 5400 ttaagacaag ctgttgcaga taaagatcaa gtgaaacgta cagaagatta tgcggatgca 60 5460 gatacagcta aacaaaatgc atataacagt gcagtttcaa gtgccgaaac aatcattaat 5520 17 2013205400 24 Apr 2013 atgcattacc acatttaaat aatgcacaaa aagcagatgt taaatctaaa catcaaatat tgctggcgta aatactgtta aacaacaagg tacagattta tgggtaactt gcaaggtgca atcaatgatg aacaaacgac gcttaatagt aagatgcgac acctagtaag aaaacagcat acacaaatgc ttttaaataa atcaaatggt caaaataaaa cgaaagatca aagtgaattc tgctaaaaat aacttagatg gtacgcgttt cagcaaaaca gcagttaaat aatatgacgc atttaacaac caaaccaaat taatagtggt actactgtcg ctggtgttca ggtacaagct agttactgaa attagatcaa tgcacaaaaa aacggttcaa atacattaga tcaagccatg aatacgttaa gacaaagtat tgccaacaaa aagcaagtga agattacgta gatgctaata atgataagca aacagcatat tagctgctgc tgaaacgatt attaatgcta atagtaatcc agaaatgaat ttacacaaaa agcagagcaa gtgaatagtt ctaaaacggc acttaacggt tagctgctgc aaaacaaaat gcgaaaacgt acttaaacac attgacaagt ctcaaaagaa caatttgatt agtcaaatta ctagtgcgac aagagtgagt ctgtaaaaca aaatgcgcaa catctagacc aagctatggc tagcttacag acaacgaatc tcaagtgaaa tcatctgaga aatatcgtga tgctgataca aagagtatga taatgctatt actgcagcga aagcgatttt aaataaatcg acactgcgca aaatgcagtt gaagcagcat tacaacgtgt taataatgcg tgaatggtga tgcaaaatta attgcagctc aaaacgcagc gaaacaacat taacgcatat cactacagct caacgtaatg atttaacaaa tcaaatttca acttagctgg tgttgaatct gttaaacaaa atgcgaatag tttagatggt acttacaaac ggctatcaac gataagtcag gaacattagc gagccaaaac ctgatgagca aaaacgtaat gcatacaatc aagctgtatc agcagccgaa caaacaacaa atccaacgat gtctgttgat gatgttaatc gtgcaacttc agctgttact 5580 tctaataaaa atgcattaaa tggttatgaa aaattagcac aatctaaaac agatgctgca 5640 5 agagcaattg 5700 attaatgctg 5760 aatacagcga 10 5820 caaaactatc 5880 gcgaaagata 5940 15 gcgatgaatc 6000 gcgaagcaaa 6060 acgaatttaa 20 6120 tcaaatgcca 6180 gatgcgacta 6240 25 aacaacgcag 6300 ccaagtacga 6360 gatgaaaact 30 6420 attacagatg 6480 ggtgttgata 6540 35 aatggtatta 6600 aataaacaac 6660 acaggtcpaa 40 6720 aaagatgcat 6780 ttaggtactt 6840 45 caagctacaa 6900 gctatgggta 6960 ttcttggatg 50 7020 accattttaa ataaacaaac tggaccgaat acagcgaaaa cagcagtcga acaagcactt 7080 aataatgtta ataatgcgaa acatgcatta aatggtacgc aaaacttaaa caatgcgaaa 7140 55 caagcagcga ttacagcaat caatggcgca tctgatttaa atcaaaaaca aaaagatgca 7200 ttaaaagcac aagctaatgg tgctcaacgc gtatctaatg cacaagatgt acagcacaat 7260 gcgactgaac tgaacacggc aatgggcaca ttaaaacatg ccatcgcaga taagacgaat 60 7320 acgttagcaa gcagtaaata tgttaatgcc gatagcacta aacaaaatgc ttacacaact 7380 18 2013205400 24 Apr 2013 aaagttacca 7440 gaagtaacag 7500 5 agattacgtg 7560 acacctcaaa 7620 caaactgttc 10 7680 attgctaacg 7740 caatcaacat 7800 15 ccgactatgg 7860 ggtttaaacg 7920 acattatcac 20 7975 atgctgaaca ctgcagctaa aagcaaaaca aagctaaatt aaacaaatgg aaacaacagt ataatagcgc ataCtagtgc gtgctgaaaa acttaacaaa tattattagc ggtacgccaa tcaagtaaac agcgcgaaac aaacgccaat actgctattg aaaagaacaa gtgggacaag acaagcattg aacaatgcaa caaaacaagt caaaactata tgtgtcaaat gcgaaaggta gattacccaa gctacaacac cttaagaaat gcacaaaaca taaccaaaaa tctgccatct cggttgttac gacaccttca aagaattaaa tggtgacgaa atgcattaac acaattaaat ccaatagatt agaagacgta tgaaaggctt aagagatagt cagacgcaag tccgaataac tcattaatca aactaacaat dagtgaataa tgctaaaaat ctgctaagca aaacttaaat catcacaaat tgatc <210> 13 <211> 2001 25 <212> DNA <213> Staphylococcus aureus <400> 13 gatcatggca ttgtatttaa tgcaagtcta cctttgtaca aagatgccat ccatcaaaaa 60 30 ggatcaatgc gcagtaatga caatggtgat gatatgagta tgatggtggg tacagtgctg 120 agtggctttg aatatcgagc gcaaaaagaa aagtatgata acttatataa attcttcaaa 180 gaaaatgaaa agaaatatca atatacaggc tttacaaaag aggcaattaa caagacacaa 35 240 aatgtcggat ataaaaatga atatttttat attacatact cttctagaag tttaaaagaa 300 tatcgaaagt attatgaacc actgattcga aaaaatgata aagaatttaa agaaggaatg 360 40 gaacgagcaa gaaaagaagt gaattacgct gcaaatacag atgctgttgc tacacttttt 420 tctactaaga aaaactttac taaagacaat acagtagatg atgtaatcga actaagtgat 480 aaattatata atttaaaaaa taaaccagat aaatctacaa tcacaataca aatagggaaa 45 540 cccactatta atactaagaa agccttttat gatgataatc gtccaataga atatggggtg 600 cacagtaaag atgaataaaa ttaatgatag ggatttaaca gaattaagta gttactgggt 660 50 ttatcaaaat attgatataa aaaaagaatt taaagttaat ggaaaaaggt ttaaacaagt 720 agacagttat aatgatgata agaatagtaa tttgaatggt gctgctgata ttaaaatata 780 tgagttatta gatgataaaa gtaaaccaac tggtcaacag acaataattt atcaaggaac 55 840 atctaatgag gcaattaatc caaataatcc attaaaatca tcggggtttg gagatgattg 900 gctccaaaat gctaaattaa tgaataatga taatgaaagc acagattatt taaagcaaac 960 60 agatcaatta tcaaatcaat ataaaataaa gttagaagat gcagatagat tatcaaatag 1020 tgatttttta aaaaaatata gaatggaatc aagtaacttc aaaaacaaaa ccattgtggc 1080 19 2013205400 24 Apr 2013 ggatggcggt aattcggaag gcggtgcagg agcaaaatat caaggagcga aacatccgaa 1140 tgaaaaagtt gttgctactg actcagcaat gattccttat gctgcttggc agaaatttgc 1200 5 tagaccacgc tttgataata tgattagttt taatagtacc aacgatttat taacatggtt 1260 acaagatcca ttcatcaaag atatgccagg aaaacgcgtt aacattaatg atggtgtgcc 1320 10 c 1380 aggttagat actttaatag acagccatgt aggttataaa aggaagttaa atagaaaaga taacacatac gatactgtac cactaatcaa aataaagtcg gtaaaagata cagaaattaa 1440 aaatggaaaa aaagtaaaaa agactattaa cataacatta gatatggatg ggcgaattcc 1500 15 aataaatgtt tggacaggag attcgattgc acgttctgga agaggaactt taattaaact 1560 taatttagaa aatcttgatg cgttgagtaa actgattact ggtgaaacaa gtggtatgtt 1620 agcagaatgc gtaatctttt taaatgaaag ttttaacatc tcagaaaatg aaaataaaaa 20 1680 ttttgcagat agaaagaaac aattatcaga aggatttaag gataagatta acttatttca 1740 gttagaagaa atggaaagaa ctttaattag taaaataaac tcacttgaag aagttgcaga 1800 25 tgaaacaata gaaagtatta gtgctgttaa acacttatta cctgattttg cattggatgc 1860 attaaaagaa agaattaatg agttgtttaa aggtataaaa tcttttatag aaaaagtgta 1920 tgatagtata gataatgaaa ttttagaaat tttcaaaaat atagatcacg acttcagaga 30 1980 tggagtatct gaagaaatga t 2001 35 <210> 14 <211> 106 <212> PRT <213> Staphylococcus aureus 40 <400> 14 Asp Gin Thr Lys Thr Gin Thr Ala His Thr Val Lys Thr Ala Gin Thr 1 5 10 15 Ala Gln Glu Gin Asn Lys Val Gin Thr Pro Val Lys Asp Val Ala Thr 45 20 25 30 Ala Lys Ser Glu Ser Asn Asn Gln Ala Val Ser Asp Asn Lys Ser Gin 35 40 45 50 Gin Thr Asn Lys Val Thr Lys His Asn Glu Thr Pro Lys Gin Ala Ser 50 55 60 Lys Ala Lys Giu Leu Pro Lys Thr Gly Leu Thr Ser Val Asp Asn Phe 65 70 75 80 55 Ile Ser Thr Val Ala Phe Ala Thr Leu Ala Leu Leu Gly Ser Leu Ser 85 90 95 Leu Leu Leu Phe Lys Arg Lys Glu Ser Lys 60 100 105 <210> 15 20 2013205400 24 Apr 2013 <211> 960 <212> PRT <213> Staphylococcus aureus 5 <400> 15 Asp Arg Ile Ile Glu Thr Ala Pro Thr Asp Tyr Leu Ser Trp Gly Val 1 5 .10 15 Gly Ala Val Gly Asn Pro Arg Phe Ile Asn Val Glu Ile Val His Thr 10 20 25 30 His Asp Tyr Ala Ser Phe Ala Arg Ser Met Asn Asn Tyr Ala Asp Tyr 35  40 45 15 Ala Ala Thr Gin Leu Gln Tyr Tyr Gly Leu Lys Pro Asp Ser Ala Glu 50 55 60 Tyr Asp Gly Asn Gly Thr Val Trp Thr His Tyr Ala Val Ser Lys Tyr 65 70 75 80 20 Leu Giy Gly Thr Asp His Ala Asp Pro His Gly Tyr Leu Arg Ser His 85 90 95 Asn Tyr Ser Tyr Asp Gin Leu Tyr Asp Leu Ile Asn Glu Lys Tyr Leu 25 100 105 110 Ile Lys Net Gly Lys Val Ala Pro Trp Gly Thr Gin Ser Thr Thr Thr 115 120 125 30 Pro Thr Thr Pro Ser Lys Pro Thr Thr Pro Ser Lys Pro Ser Thr Gly 130 135 140 Lys Leu Thr Val Ala Ala Asn Asn Gly Val Ala Gin Ile Lys Pro Thr 145 150 155 160 35 Asn Ser Gly Leu Tyr Thr Thr Val Tyr Asp Lys Thr Gly Lys Ala Thr 165 170 175 Asn Glu Val Gin Lys Thr Phe Ala Val Ser Lys Thr Ala Thr Leu Gly 40 180 185 190 Asn Gin Lys Phe Tyr Leu Val Gin Asp Tyr Asn Ser Gly Asn Lys Phe 195 200 205 45 Giy Trp Val Lys Glu Gly Asp Val Val Tyr Asn Thr Ala Lys Ser Pro 210 215 220 Val Asn Val Asn Gln Ser Tyr Ser Ile Lys Pro Giy Thr Lys Leu Tyr 225 230 ' 235 240 50 Thr Val Pro Trp Gly Thr Ser Lys Gin Val Ala Gly Ser Val Ser Gly 245 250 255 Ser Gly Asn Gin Thr Phe Lys Ala Ser Lys Gln Gln Gin Ile Asp Lys 55 260 265 270 Ser Ile Tyr Leu Tyr Gly Ser Val Asn Gly Lys Ser Gly Trp Val Ser 275 280 285 60 Lys Ala Tyr Leu Val Asp Thr Ala Lys Pro Thr Pro Thr Pro Thr Pro 290 295 300 Lys Pro Ser Thr Pro Thr Thr Asn Asn Lys Leu Thr Val Ser Ser Leu 21 2013205400 24 Apr 2013 305 310 315 320 Asn Gly Val Ala Gin lie Asn Ala Lys Asn Asn Gly Leu Phe Thr Thr 325 330 335 5 Val Tyr Asp Lys Thr Gly Lys Pro Thr Lys Glu Val Gln Lys Thr Phe 340 345 350 Ala Val Thr Lys Glu Ala Ser Leu Gly Gly Asn Lys Phe Tyr Leu Val 10 355 360 365 Lys Asp Tyr Asn Ser Pro Thr Leu Ile Gly Trp Val Lys Gin Gly Asp 370 375 380 15 Val Ile Tyr Asn Asn Ala Lys Ser Pro Val Asn Val Met Gin Thr Tyr 385 390 395 400 Thr Val Lys Pro Gly Thr Lys Leu Tyr Ser Val Pro Trp Gly Thr Tyr 405 410 415 20 Lys Gin Glu Ala Gly Ala Val Ser Gly Thr Gly Asn Gin Thr Phe Lys 420 425 430 Ala Thr Lys Gln Gin Gin Ile Asp Lys Ser Ile Tyr Leu Phe Gly Thr 25 435 440 445 Val Asn Gly Lys Ser Gly Trp Val Ser Lys Ala Tyr Leu Ala Val Pr() 450 455 460 30 Ala Ala Pro Lys Lys Ala Val Ala Gin Pro Lys Thr Ala Val Lys Ala 465 470 475 480 Tyr Thr Val Thr Lys Pro Gin Thr Thr Gin Thr Val Ser Lys Ile Ala 485 490 495 35 Gin Val Lys Pro Asn Asn Thr Gly Ile Arg Ala Ser Val Tyr Glu Lys 500 505 510 Thr Ala Lys Asn Gly Ala Lys Tyr Ala Asp Arg Thr Phe Tyr Val Thr 40 515 520 525 Lys Glu Arg Ala His Gly Asn Glu Thr Tyr Val Leu Leu Asn Asn Thr 530 535 540 45 Ser His Asn Ile Pro Leu Gly Trp Phe Asn Val Lys Asp Leu Asn Val 545 550 555 560 Gin Asn Leu Gly Lys Glu Val Lys Thr Thr Gin Lys Tyr Thr Val Asn 565 570 575 50 Lys Ser Asn Asn Gly Leu Ser Met Val Pro Trp Gly Thr Lys Asn Gin 580 585 590 Val Ile Leu Thr Gly Asn Asn Ile Ala Gin Gly Thr Phe Asn Ala Thr 55 595 600 605 Lys Gin Val Ser Val Gly Lys Asp Val Tyr Leu Tyr Gly Thr Ile Asn 610 615 620 60 Asn Arg Thr Gly Trp Val Asn Ala Lys Asp Leu Thr Ala Pro Thr Ala 625 630 635 640 Val Lys Pro Thr Thr Ser Ala Ala Lys Asp Tyr Asn Tyr Thr Tyr Val 22 2013205400 24 Apr 2013 645 650 655 Ile Lys Asn Gly Asn Gly Tyr Tyr Tyr Val Thr Pro Asn Ser Asp Thr 660 665 670 5 Ala Lys Tyr Ser Leu Lys Ala Phe Asn Glu Gin Pro Phe Ala Val Val 675 680 685 Lys Glu Gln Val Ile Asn Gly Gin Thr Trp Tyr Tyr Gly Lys Leu Ser 10 690 695 700 Asn Gly Lys Leu Ala Trp Ile Lys Ser Thr Asp lieu Ala Lys Glu Leu 705 710 715 720 15 Ile Lys Tyr Asn Gln Thr Gly Met Ala Leu Asn Gin Val Ala Gin Ile 725 730 735 Gin Ala Gly Leu Gin Tyr Lys Pro Gin Val Gln Arg Val Pro Gly Lys 740 745 750 20 Trp Thr Gly Ala Asn Phe Asn Asp Val Lys His Ala Met Asp Thr Lys 755 760 765 Arg Leu Ala Gin Asp Pro Ala Leu Lys Tyr Gin Phe Leu Arg Leu Asp 25 770 775 780 Gin Pro Gln Asn Ile Ser Ile Asp Lys Ile Asn Gin Phe Leu Lys Gly 785 790 795 800 30 Lys Gly Val Leu Glu Asn Gin Gly Ala Ala Phe Asn Lys Ala Ala Gin 805 810 815 Met Tyr Gly Ile Asn Glu Val Tyr Leu Ile Ser His Ala Leu Leu Glu 820 825 830 35 Thr Gly Asn Gly Thr Ser Gin Leu. Ala Lys Gly Ala Asp Val Val Asn 835 840 845 Asn Lys Val Val Thr Asn Ser Asn Thr Lys Tyr His Asn Val Phe Gly 40 850 855 860 Ile Ala Ala Tyr Asp Asn Asp Pro Leu Arg Glu Gly Ile Lys Tyr Ala 865 870 875 880 45 Lys Gln Ala Gly Trp Asp Thr Val Ser Lys Ala Ile Val Gly Gly Ala 885 890 895 Lys Phe Ile Gly Asn Ser Tyr Val Lys Ala Gly Gln Asn Thr Leu Tyr 900 905 910 50 Lys Met Arg Trp Asn Pro Ala His Pro Gly Thr His Gin Tyr Ala Thr 915 920 925 Asp Val Asp Trp Ala Asn Ile Asn Ala Lys Ile Ile Lys Gly Tyr Tyr 55 930 935 940 Asp Lys Ile Gly Giu Val Gly Lys Tyr Phe Asp Ile Pro Gin Tyr Lys 945 950 955 960 60 23 2013205400 24 Apr 2013 5 <210> 16 <211> 386 <212> PRT <213> Staphylococcus aureus <400> 16 Asp Gln Tyr 1 10 Gln Ser Lys Leu Pro Thr 35 15 Ser Glu Asp Ala Lys Lys Thr Gin Lys Asp Tyr Ala Ser 5 10 15 Lys Asp Lys Asn Glu Lys Sex . Asn Thr Lys Asn Pro Gin 20 25 30 Gin Asp Glu Leu Lys His Lys Ser Lys Pro Ala Gin Ser 40 45 Phe Asn Asn Asp Val Asn Gin Lys Asp Thr Arg Ala Thr Ser Leu Phe 50 55 60 Glu Thr Asp Pro Ser Ile Ser Asn Asn Asp Asp Ser Gly Gin Phe Asn 20 65 70 75 80 Val Val Asp Ser Lys Asp Thr Arg Gln Phe Val Lys Ser Ile Ala Lys 85 90 95 25 Asp Ala His Arg Ile Gly Gin Asp Asn Asp Ile Tyr Ala Sex Val Met 100 105 110 Ile Ala Gin Ala Ile Leu Glu Sex Asp Ser Gly Arg Ser Ala Leu Ala 115 120 125 30 Lys Sex Pro Asn His Asn Leu Phe Gly Ile Lys Gly Ala Phe Glu Gly 130 135 140 Asn Sex Val Pro Phe Asn Thr Leu Glu Ala Asp Gly Asn Gln Leu Tyr 35 145 150 155 160 Sex Ile Asn Ala Gly Phe Arg Lys Tyr Pro Ser Thr Lys Gin Ser Leu 165 170 175 40 Lys Asp Tyr Ile Tyr Lys 195 45 Thr Ser His 210 Lys Leu Asn 50 225 Giu Arg Met 55 Asp Asp Ser Met Pro Tyr 275 60 Ser Asp Leu Ile Lys Asn Gly Ile Asp Gly Asn Arg Thr 180 185 190 Pro Thr Trp Lys Ser Giu Ala Asp Ser Tyr Lys Asp Ala 200 205 Leu Sex Lys Thr Tyr Ala Thr Asp Pro Asn Tyr Ala Lys 215 220 Ser. Ile Ile Lys His Tyr Gln Leu Thr Gin Phe Asp Asp 230 235 290 Pro Asp Leu Asp Lys Tyr Glu Arg Ser Ile Lys Asp Tyr 245 250 255 Ser Asp Glu Phe Lys Tro Phe Arg Giu Val Sex Asp Sex 260 265 270 Pro His Gly Gln Cys Thr Trp Tyr Val Tyr Asn Arg Met 280 285 Lys Gin Phe Gly Thr Ser Ile Ser Gly Asp Len Gly Asp Ala His Asn 290 295 300 24 2013205400 24 Apr 2013 Trp Asn Asn Arg Ala Gln Tyr Arg Asp Tyr Gln Val Ser His Thr Pro 305 310 315 320 Lys Arg His Ala Ala Val Val Phe Glu Ala Gly Gin Phe Gly Ala Asp 5 325 330 335 Gin His Tyr Gly His Val Ala Phe Val Glu Lys Val Asn Ser Asp Gly 340 345 350 10 Ser Ile Val Ile Ser Glu Ser Asn Val Lys Gly Leu Gly Ile Ile Ser 355 360 365 His Arg Thr Ile Asn Ala Ala Ala Ala Glu Glu Leu Ser Tyr Ile Thr 370 375 380 15 Gly Lys 385 20 <210> 17 <211> 325 <212> PRT <213> Staphylococcus aureus 25 <400> 17 Met Lys Met Asn Lys Leu Val Lys Her Ser Val Ala Thr Ser Met Ala 1 5 10 15 Leu Leu Leu Leu Ser Giy Thr Ala Asn Ala Glu Gly Lys Ile Thr Pro 30 20 25 30 Val Ser Val Lys Lys Val Asp Asp Lys Val Thr Leu Tyr Lys Thr Thr 35 40 45 35 Ala Thr Ala Asp Ser Asp Lys Phe Lys Ile Ser Gin Ile Leu Thr Phe 50 55 60 Asn Phe Ile Lys Asp Lys Ser Tyr Asp Lys Asp Thr Leu Val Leu Lys 65 70 75 80 Ala Thr Gly Asn Ile Asn Ser Gly Phe Val Lys Pro Asn Pro Asn Asp 85 90 95 Tyr Asp Phe Her Lys Leu Tyr Trp Gly Ala Lys Tyr Asn Val Ser Ile 45 100 105 110 Ser Ser Gln Ser Asn Asp Ser Val Asn Val Val Asp Tyr Ala Pro Lys 115 120 125 50 Asn Gln Asn Glu Glu Phe Gln Val Gin Asn Thr Leu Giy Tyr Thr Phe 130 135 140 Gly Gly Asp Ile Ser Ile Ser Asn Gly Leu Ser Gly Gly Leu Asn Gly 145 150 155 160 55 Asn Thr Ala Phe Ser Glu Thr Ile Asn Tyr Lys Gln Glu Ser Tyr Arg 165 170 175 Thr Thr Leu Ser Arg Asn Thr Asn Tyr Lys Asn Val Gly Trp Giy Val 60 180 185 190 Glu Ala His Lys Ile Met Asn Asn Gly Trp Giy Pro Tyr Gly Arg Asp 195 200 205 40 25 2013205400 24 Apr 2013 Ser Phe His Pro Thr Tyr Gly Asn Giu Leu Phe Leu Ala Gly Arg Gin 210 215 220 5 Ser Her Ala Tyr Ala Gly Gin Asn Phe Ile Ala Gin His Gin Met Pro 225 230 235 240 Leu Leu Her Arg Ser Asn Phe Asn Pro Glu Phe Leu Ser Val Leu Ser 245 250 255 10 His Arg Gin Asp Gly Ala Lys Lys Sex Lys Ile Thr Val Thr Tyr Gin 260 265 270 Arg Glu Met Asp Leu Tyr Gin Ile Arg Trp Asn Gly Phe Tyr Trp Ala 15 275 280 285 Giy Ala Asn Tyr Lys Asn Phe Lys Thr Arg Thr Phe Lys Ser Thr Tyr 290 295 300 20 Glu Ile Asp Trp Giu Asn His Lys Val Lys Leu Leu Asp Thr Lys Glu 305 310 315 320 Thr Glu Asn Asn Lys 325 25 <210> 18 <211> 157 <212> PRT 30 <213> Staphylococcus aureus <400> 18 Ser Phe Asn Tyr Ser Lys Ser Ile Ser Tyr Thr Gin Gin Asn Tyr Val 1 5 10 15 35 Ser Glu Val Glu Gln Gin Asn Her Lys Ser Val Leu Trp Giy Val Lys 20 25 30 Ala Asn Ser Phe Ala Thr Glu Ser Gly Gin Lys Ser Ala Phe Asp Ser 40 35 40 45 Asp Leu Phe Val Gly Tyr Lys Pro His Ser Lys Asp Pro Arg Asp Tyr 50 55 60 45 Phe Val Pro Asp Ser Glu Leu Pro Pro Leu Val Gin Ser Gly Phe Asn 65 70 75 80 Pro Ser Phe Ile Ala Thr Val Ser His Giu Lys Gly Ser Sex Asp Thr 90 95 Ser Glu Phe Giu Ile Thr Tyr Gly Arg Asn Met Asp Val Thr His Ala 100 105 110 Ile Lys Arg Her Thr His Tyr Gly Asn Ser Tyr Leu Asp Gly His Arg 55 115 120 125 Val His Asn Ala Phe Val Asn Arg Asn Tyr Thr Val Lys Tyr Glu Val 130 135 140 60 Asn Trp Lys Thr His Glu Ile Lys Val Lys Gly Gln Asn 145 150 155 85 50 26 2013205400 24 Apr 2013 <210> 19 <211> 345 <212> PRT <213> Staphylococcus aureus 5 <400> 19 Ile Ile Ala Ile Ile Ile Leu Ile Phe Ile Ser Phe Phe Phe Ser Gly 1 5 10 15 10 Ser Glu Thr Ala Leu Thr Ala Ala Asn Lys Ala Lys Phe Lys Thr Glu 20 25 30 Ala Asp Lys Gly Asp Lys Lys Ala Lys Gly Ile Val Lys Leu Leu Glu 35 40 45 15 Lys Pro Sex Glu Phe Ile Thr Thr Ile Leu Ile Gly Asn Asn Val Ala 50 55 60 Asn Ile Leu Leu Pro Thr Leu Val Thr Ile Met Ala Leu Arg Trp Gly 20 65 70 75 80 Ile Ser Val Gly Ile Ala Ser Ala Val Leu Thr Val Val Ile Ile Leu 85 90 95 25 Ile Ser Glu Val Ile Pro Lys Ser Val Ala Ala Thr Phe Pro Asp Lys 100 105 110 Ile Thr Arg Leu Val Tyr Pro Ile Ile Asn Ile Cys Val Ile Val Phe 115 120 125 30 Arg Pro Ile Thr Leu Leu Leu Asn Lys Leu Thr Asp Sex Ile Asn Arg 130 135 140 Ser Leu Sex Lys Gly Gin Pro Gin Glu His Gin Phe Ser Lys Glu Glu 35 145 150 155 160 Phe Lys Thr Met Leu Ala Ile Ala Gly His Glu Gly Ala Leu Asn Glu 165' 170 175 40 Ile Glu Thr Ser Arg Leu Glu Gly Val Ile Asn Phe Glu Asn Leu Lys 180 185 190 Val Lys Asp Val Asp Thr Thr Pro Arg Ile Asn Val Thr Ala Phe Ala 195 200 205 45 Ser Asn Ala Thr Tyr Giu Glu Val Tyr Glu Thr Val Met Asn Lys Pro 210 215 220 Tyr Thr Arg Tyr Pro Val Tyr Glu Gly Asp Ile Asp Asn Ile Ile Gly 50 225 230 235 240 Val Phe His Ser Lys Tyr Leu Leu Ala Trp Ser Asn Lys Lys Glu Asn 245 250 255 55 Gin Ile Thr Asn Tyr Ser Ala Lys Pro Leu Phe Val Asn Glu His Asn 260 265 270 Lys Ala Glu Trp Val Leu Arg Lys Met Thr Ile Ser Arg Lys His Leu 275 280 285 60 Ala Ile Val Leu Asp Glu Phe Gly Gly Thr Giu Ala Ile Val Ser His 290 295 300 27 2013205400 24 Apr 2013 Met Ser Asn 35 25 Asn Thr Glu 50 Thr Ser Glu 30 65 Gly Glu Ala Gln Lys Ala Val Ser Asn Lys Glu 85 35 Lys Glu Val Lys Glu 100 Pro Ala Ala Lys Ala 115 40 Leu Ile Arg Ser Asp 130 Glu Asp Leu Ile Glu Glu Leu Leu Gly Met Glu Ile Glu Asp Glu Met 305 310 315 320 Asp Lys Lys Glu Lys Glu Lys Leu Ser Gin Gin Gin 5 325 330 Gin Arg Lys Asn Arg Asn Val Ser Ile 340 345 10 <210> 20 <211> 133 <212> PRT <213> Staphylococcus aureus 15 Ile Gin Phe Gin 335 <400> 20 Met Asn Lys Gin Gln Lys Glu Phe Lys Ser Phe Tyr Ser Ile Arg Lys 1 5 10 15 20 Sex Ser Leu Gly Val Ala Ser Val Ala Ile Ser Thr Leu Leu Leu Leu 20 25 30 Ala Gin Ala Ala Ala Glu Glu Thr Gly Gly Thr 40 45 Pro Lys Thr Glu Ala Val Ala Ser Pro Thr Thr 55 60 Pro Glu Thr Lys Pro Val Ala Asn Ala Val Ser 70 75 80 Val Glu Ala Pro Thr Ser Glu Thr Lys Glu Ala 90 95 Val Lys Ala Pro Lys Glu Thr Lys Glu Val Lys 105 110 Thr Asn Asn Thr Tyr Pro Ile Leu Asn Gln Glu 120 125 45 <210> 21 <211> 205 <212> PRT <213> Staphylococcus aureus 50 <400> 21 Asp His Gly Ile Val Phe Asn Ala Ser Leu Pro Leu Tyr Lys Asp Ala 1 5 10 15 Ile His Gin Lys 55 20 Gly Ser Met Arg Ser 25 Asn Asp Asn Gly Asp Asp Met 30 Ser Met Met Val Gly Thr Val Leu Ser Gly Phe Glu Tyr Arg Ala Gln 35 40 45 60 Lys Glu Lys Tyr Asp Asn Leu Tyr Lys Phe Phe Lys Glu Asn Glu Lys 50 55 60 Lys Tyr Gln Tyr Thr Gly Phe Thr Lys Glu Ala lie Asn Lys Thr Gin 28 2013205400 24 Apr 2013 65 70 75 80 Asn Val Gly Tyr Lys Asn Glu Tyr Phe Tyr Ile Thr Tyr Ser Sex Arg 85 90 95 5 Ser Leu. Lys Glu Tyr Arg Lys Tyr Tyr Glu Pro Leu Ile Arg Lys Asn 100 105 110 Asp Lys Glu Phe Lys Glu Gly Met Glu Arg Ala Arg Lys Glu Val Asn 10 115 120 125 Tyr Ala Ala Asn Thr Asp Ala Val Ala Thr Leu Phe Ser Thr Lys Lys 130 135 140 15 Asn Phe Thr Lys Asp Asn Thr Val Asp Asp Val Ile Glu Leu Ser Asp 145 150 155 160 Lys Leu Tyr Asn Leu Lys Asn Lys Pro Asp Lys Ser Thr Ile Thr Ile 165 170 175 20 Gln Ile Gly Lys Pro Thr Ile Asn Thr Lys Lys Ala Phe Tyr Asp Asp 180 185 190 Asn Arg Pro Ile Glu Tyr Gly Val His Ser Lys Asp Glu 25 195 200 205 <210> 22 <211> 510 30 <212> PRT <213> Staphylococcus aureus <400> 22 Asp His Tyr Val Ile Gln Tyr Phe Ser Gly Leu Ile Gly Gly Arg Gly 35 1 5 10 15 Arg Arg Ala Asn Leu Tyr Gly Leu Phe Asn Lys Ala Ile Glu Phe Glu 20 25 30 40 Asn Ser Ser Phe Arg Gly Leu Tyr Gin Phe Ile Arg Phe Ile Asp Glu 35 40 45 Leu Ile Glu Arg Gly Lys Asp Phe Gly Glu Glu Asn Val Val Gly Pro 55 60 Asn Asp Asn Val Val Arg Met Met Thr Ile His Ser Ser Lys Gly Leu 65 70 75 BO Glu Phe Pro Phe Val Ile Tyr Ser Gly Leu Ser Lys Asp Phe Asn Lys 50 85 90 95 Arg Asp Leu Lys Gln Pro Val Ile Leu Asn Gin Gin Phe Gly Leu Gly 100 105 110 55 Met Asp Tyr Phe Asp Val Asp Lys Glu Met Ala Phe Pro Ser Leu Ala 115 120 125 Ser Val Ala Tyr Arg Ala Val Ala Glu Lys Glu Leu Val Ser Glu Glu 130 135 140 60 Met Arg Leu Val Tyr Val Ala Leu Thr Arg Ala Lys Glu Gln Leu Tyr 145 150 155 160 50 45 29 2013205400 24 Apr 2013 Leu Ile Gly Arg Val Lys Asn Asp Lys Ser Leu Leu Glu Glu Gin 60 165 170 175 Leu Ser Ile Ser Gly Glu His Ile Ala Val Asn Glu Arg Leu Thr Ser 5 180 185 190 Pro Asn Pro Phe His Lou Ile Tyr Ser Ile Leu Ser Lys His Gin Ser 195 200 205 10 Ala Her Ile Pro Asp Asp Leu Lys Phe Glu Lys Asp Ile Ala Gin Ile 210 215 220 Glu Asp Ser Her Arg Pro Asn Val Asn Ile Ser Ile Val Tyr Phe Glu 225 230 235 240 15 Asp Val Her Thr Glu Thr Tie Leu Asp Asn Asp Glu Tyr Arg Ser Val 245 25D 255 Asn Gin Lou Giu Thr Met Gln Asn Gly Asn Glu Asp Val Lys Ala Gin 20 260 265 270 Ile Lys His Gin Leu Asp Tyr Arg Tyr Pro Tyr Val Asn Asp Thr Lys 275 280 285 25 Lys Pro Ser Lys Gln Ser Val Her Giu Lou Lys Arg Gin Tyr Giu Thr 290 295 300 Glu Glu Ser Gly Thr Ser Tyr Glu Arg Val Arg Gln Tyr Arg Ile Gly 305 310 315 320 30 Phe Ser Thr Tyr Glu Arg Pro Lys Phe Leu Ser Glu Gin Gly Lys Arg 325 330 335 Lys Ala Asn Giu Ile Gly Thr Leu Met His Thr Val Met Gln His Leu 35 340 345 350 Pro Phe Lys Lys Glu Arg Ile Ser Giu Val Glu Lou His Gin Tyr Ile 355 360 365 40 Asp Gly Leu Ile Asp Lys His Ile Ile Glu Ala Asp Ala Lys Lys Asp 370 375 380 Ile Arg Met Asp Glu Ile Met Thr Phe Ile Asn Ser Glu Lou Tyr Ser 385 390 395 400 45 Ile Ile Ala Glu Ala Glu Gln Val Tyr Arg Glu Leu Pro Phe Val Val 405 410 415 Asn Gin Ala Lou Val Asp Gln Leu Pro Gin Gly Asp Giu Asp Val Ser 50 420 425 430 Ile Ile Gin Gly Met lie Asp Leu Ile Phe Val Lys Asp Gly Val His 435 440 445 55 Tyr Phe Val Asp Tyr Lys Thr Asp Ala Phe Asn Arg Arg Arg Gly Met 450 455 460 Thr Asp Giu Glu Ile Gly Thr Gin Leu Lys Asn Lys Tyr Lys Ile Gln 465 470 475 480 Met Lys Tyr Tyr Gin Asn Thr Leu Gln Thr Ile Leu Asn Lys Glu Val 485 490 495 30 2013205400 24 Apr 2013 Lys Gly Tyr Leu Tyr Phe Phe Lys Phe Gly Thr Leu Gln Leu 500 505 510 5 <210> 23 <211> 124 <212> PRT <213> Staphylococcus aureus 10 <400> 23 Met Lys Phe Leu Ser Phe Lys Tyr Asn Asp Lys Thr Ser Tyr Gly Val 1 5 10 15 Lys Val Lys Arg Glu Asp Ala Val Trp Asp Leu Thr Gin Val Phe Ala 15 20 25 30 Asp Phe Ala Glu Gly Asp Phe His Pro Lys Thr Leu Leu Ala Gly Leu. 35 40 45 20 Gln Gin Asn His Thr Leu Asp Phe Gln Glu Gin Val Arg Lys Ala Val 50 55 60 Val Ala Ala Glu Asp Ser Gly Lys Ala Glu Asp Tyr Lys Ile Ser Phe 65 70 75 80 25 Asn Asp Ile Glu Phe Leu Pro Pro Val Thr Pro Pro Asn Asn Val Ile 85 90 95 Ala Phe Gly Arg Asn Tyr Lys Asp His Ala Asn Glu Leu Asn His Glu 30 100 105 110 Val Glu Lys Leu Tyr Val Phe Thr Lys Ala Ala Ser 115 120 <210> 24 <211> 180 <212> PRT <213> Staphylococcus aureus <400> 24 Ser Gly Thr Gly Phe Ile Val Gly Lys Asn Thr Ile Val Thr Asn Lys 1 5 10 15 45 His Val Val Ala Gly Met Glu Ile Gly Ala His Ile Ile Ala His Pro 20 25 30 Asn Gly Glu Tyr Asn Asn Gly Gly Phe Tyr Lys Val Lys Lys Ile Val 35 40 45 50 Arg Tyr Ser Gly Gin Glu Asp Ile Ala Ile Leu His Val Glu Asp Lys 50 55 60 Ala Val His Pro Lys Asn Arg Asn Phe Lys Asp Tyr Thr Gly Ile Leu 55 65 70 75 80 Lys Ile Ala Ser Glu Ala Lys Glu Asn Glu Arg Ile Her Ile Val Gly 85 90 95 60 Tyr Pro Glu Pro Tyr Ile Asn Lys Phe Gin Met Tyr Glu Her Thr Gly 100 105 110 Lys Val Leu Ser Val Lys Gly Asn Met Ile Ile Thr Asp Ala Phe Val 35 40 31 2013205400 24 Apr 2013 115 120 125 Glu Pro Gly Asn Ser Gly Ser Ala Val Phe Asn Sex Lys Tyr Glu Val 130 135 140 5 Val Gly Val His Phe Gly Gly Asn Gly Pro Gly Asn Lys Ser Thr Lys 145 150 155 160 Gly Tyr Gly Val Tyr Phe Ser Pro Glu Ile Lys Lys Phe Ile Ala Asp 10 165 170 175 Asn Thr Asp Lys 180 <210> 25 <211> 239 <212> PRT <213> Staphylococcus aureus <400> 25 Met Asn Lys Asn Ile Ile Ile Lys Ser Ile Ala Ala Leu Thr Ile Leu 1 5 10 15 25 Thr Ser Ile Thr Gly Val Gly Thr Thr Met Val Glu Gly Ile Gln Gin 20 25 30 Thr Ala Lys Ala Glu Asn Thr Val Lys Gln Ile Thr Asn Thr Asn Val 35 40 45 30 Ala Pro Tyr Ser Gly Val Thr Tip Met Gly Ala Gly Thr Gly Phe Val 50 55 60 Val Gly Asn His Thr Ile Ile Thr Asn Lys His Val Thr Tyr His Met 35 65 70 75 80 Lys Val Gly Asp Glu Ile Lys Ala His Pro Asn Gly Phe Tyr Asn Asn 85 90 95 40 Gly Gly Gly Leu Tyr Lys Val Thr Lys Ile Val Asp Tyr Pro Gly Lys 100 105 110 Glu Asp Ile Ala Val Val Gln Val Glu Glu Lys Ser Thr Gin Pro Lys 115 120 125 45 Gly Arg Lys Phe Lys Asp Phe Thr Ser Lys Phe Asn Ile Ala Ser Glu 130 135 140 Ala Lys Glu Asn Glu Pro Ile Ser Val Ile Gly Tyr Pro Asn Pro Asn 50 145 150 155 160 Gly Asn Lys Leu Gin Met Tyr Glu Ser Thr Gly Lys Val Lou Ser Val 165 170 175 55 Asn Gly Asn Ile Val Ser Ser Asp Ala Ile Ile Gin Pro Gly Ser Ser 180 185 190 Gly Ser Pro Ile Leu Asn Ser Lys His Glu Ala Ile Gly Val Ile Tyr 195 200 205 Ala Gly Asn Lys Pro Ser Gly Glu Ser Thr Arg Gly Phe Ala Val Tyr 210 215 220 15 20 60 32 2013205400 24 Apr 2013 Phe Ser Pro Glu Ile Lys Lys Phe Ile Ala Asp Asn Leu Asp Lys 225 230 235 5 <210> 26 <211> 470 <212> PRT <213> Staphylococcus aureus 10 <400> 26 Met Gly Cys Thr Val Lys Met Asn Lys Ile Asn Asp Arg Asp Leu Thr 1 5 10 15 Glu Leu Ser Ser Tyr Trp Val Tyr Gln Asn Ile Asp Ile Lys Lys Glu 15 20 25 30 Phe Lys Va1 Asn Gly Lys Arg Phe Lys Gln Va1 Asp Ser Tyr Asn Asp 35 40 45 20 Asp Lys Asn Ser Asn Leu Asn Gly Ala Ala Asp Ile Lys Ile Tyr Glu 50 55 60 Leu Leu Asp Asp Lys Ser Lys Pro Thr Gly Gin Gin Thr Ile Ile Tyr 65 70 75 80 25 Gin Gly Thr Ser Asn Glu Ala Ile Asn Pro Asn Asn Pro Leu Lys Ser 85 90 95 Her Gly Phe Giy Asp Asp Trp Leu Gin Asn Ala Lys Leu Met Asn Asn 30 100 105 110 Asp Asn Glu Her Thr Asp Tyr Leu Lys Gin Thr Asp Gln Leu Ser Asn 115 120 125 35 Gln Tyr Lys Ile Lys Leu Glu Asp Ala Asp Arg Leu Ser Asn Ser Asp 130 135 140 Phe Leu Lys Lys Tyr Arg Met Glu Ser Ser Asn Phe Lys Asn Lys Thr 145 150 155 160 40 Ile Val Ala Asp Gly Gly Asn Her Glu Giy Gly Ala Gly Ala Lys Tyr 165 170 175 Gin Gly Ala Lys His Pro Asn Glu Lys Val Val Ala Thr Asp Ser Ala 45 180 185 190 Met Ile Pro Tyr Ala Ala Trp Gin Lys Phe Ala Arg Pro Arg Phe Asp 195 200 205 50 Asn Met Ile Ser Phe Asn Ser Thr Asn Asp Leu Leu Thr Trp Leu Gin 210 215 220 Asp Pro Phe Ile Lys Asp Met Pro Gly Lys Arg Val Asn Ile Asn Asp 225 230 235 240 55 Gly Val Pro Arg Leu Asp Thr Leu Ile Asp Ser His Val Gly Tyr Lys 245 250 255 Arg Lys Leu Asn Arg Lys Asp Asn Thr Tyr Asp Thr Val Pro Leu lie 60 260 265 270 Lys Ile Lys Ser Val Lys Asp Thr Glu Ile Lys Asn Gly Lys Lys Val 275 280 285 33 2013205400 24 Apr 2013 Lys Lys Thr Ile Asn Ile Thr Leu Asp Met Asp Gly Arg Ile Pro Ile 290 295 300 5 Asn Val Trp Thr Gly Asp Ser Ile Ala Arg Ser Gly Arg Gly Thr Leu 305 310 315 320 Ile Lys Leu Asn Leu Glu Asn Leu Asp Ala Leu Ser Lys Leu Ile Thr 325 330 335 10 Gly Glu Thr Ser Gly Met Leu Ala Glu Cys Val lie Phe Leu Asn Glu 340 345 350 Ser Phe Asn Ile Ser Glu Asn Glu Asn Lys Asn Phe Ala Asp Arg Lys 15 355 360 365 Lys Gin Leu Ser Glu Gly Phe Lys Asp Lys Ile Asn Leu Phe Gin Leu 370 375 380 20 Glu Glu Met Glu Arg Thr Leu Ile Ser Lys Ile Asn Ser Leu Giu Glu 385 390 395 400 Val Ala Asp Glu Thr Ile Glu Ser Ile Ser Ala Val Lys His Leu Leu 405 410 415 25 Pro Asp Phe Ala Leu Asp Ala Leu Lys Glu Arg Ile ' Asn Giu Leu Phe 420 425 430 Lys Gly Ile Lys Ser Phe Ile Glu Lys Val Tyr Asp Ser Ile Asp Asn 30 435 440 445 Glu Ile Leu Glu Ile Phe Lys Asn Ile Asp His Asp Phe Arg Asp Gly 450 455 460 35 Val Ser Giu Giu Met Met 465 470 <210> 27 40 <211> 306 <212> PRT <213> Staphylococcus aureus <400> 27 45 Met Lys Lys Lys Asp Gly Thr Gin Gln Phe Tyr His Tyr Ala Ser Ser 1 5 10 15 Val Lys Pro Ala Arg Val Ile Phe Thr Asp Ser Lys Pro Glu Ile Glu 20 25 30 50 Leu Gly Leu Gin Ser Gly Gln Phe Trp Arg Lys Phe Glu Val Tyr Glu 35 40 45 Gly Asp Lys Lys Leu Pro Ile Lys Leu Val Ser Tyr Asp Thr Val Lys 55 50 55 60 Asp Tyr Ala Tyr Ile Arg Phe Her Val Ser Asn Gly Thr Lys Ala Val 65 70 75 80 60 Lys Ile Val Ser Ser Thr His Phe Asn Asn Lys Glu Glu Lys Tyr Asp 85 90 95 Tyr Thr Leu Met Giu Phe Ala Gin Pro Ile Tyr Asn Ser Ala Asp Lys 34 2013205400 24 Apr 2013 100 105 110 Phe Lys Thr Glu Glu Asp Tyr Lys Ala Glu Lys Leu Leu Ala Pro Tyr 115 120 125 5 Lys Lys Ala Lys Thr Leu Glu Arg Gin Val Tyr Glu Leu Asn Lys Ile 130 135 140 Gln Asp Lys Leu Pro Glu Lys Leu Lys Ala Glu Tyr Lys Lys Lys Leu 10 145 150 155 160 Glu Asp Thr Lys Lys Ala Leu Asp Glu Gin Val Lys Ser Ala Ile Thr 165 170 175 15 Glu Phe Gin Asn Val Gin Pro Thr Asn Glu Lys Met Thr Asp Leu Gin 180 185 190 Asp Thr Lys Tyr Val Val Tyr Glu Ser Val Glu Asn Asn Glu Ser Met 195 200 205 20 Met Asp Thr Phe Val Lys His Pro Ile Lys Thr Gly Met Leu Asn Gly 210 215 220 Lys Lys Tyr Met Val Met Glu Thr Thr Asn Asp Asp Tyr Trp Lys Asp 25 225 230 235 240 Phe Met Val Glu Gly Gln Arg Val Arg Thr Ile Her Lys Asp Ala Lys 245 250 255 30 Asn Asn Thr Arg Thr Ile Ile Phe Pro Tyr Val Glu Gly Lys Thr Leu 260 265 270 Tyr Asp Ala Ile Val Lys Val His Val Lys Thr Ile Asp Tyr Asp Gly 275 280 285 35 Gin Tyr His Val Arg Ile Val Asp Lys Glu Ala Phe Thr Lys Ala His 290 295 300 Thr Asp 40 305 <210> 28 <211> 2659 45 <212> PRT <213> Staphylococcus aureus <400> 28 Asp Gin Thr Thr Ile Ile Asn Ser Leu Thr Phe Thr Glu Thr Val Pro 50 1 5 10 15 Asn Arg Ser Tyr Ala Arg Ala Ser Ala Asn Glu Ile Thr Ser Lys Thr 20 25 30 55 Val Ser Asn Val Ser Arg Thr Gly Asn Asn Ala Asn Val Thr Val Thr 35 40 45 Val Thr Tyr Gin Asp Gly Thr Thr Ser Thr Val Thr Val Pro Val Lys 50 55 60 60 His Val Ile Pro Glu Ile Val Ala His Ser His Tyr Thr Val Gln Gly 65 70 75 80 35 2013205400 24 Apr 2013 Gin Asp Phe Pro Ala Gly Asn Gly Ser Sex Ala Ser Asp Tyr Phe Lys 85 90 95 Leu Ser Asn Gly Ser Asp Ile Ala Asp Ala Thr Ile Thr Trp Val Sex 5 100 105 110 Gly Gin Ala Pro Asn Lys Asp Asn Thr Arg Ile Gly Glu Asp Ile Thr 115 120 125 10 Val Thr Ala His Ile Leu Ile Asp Gly Glu Thr Thr Pro Ile Thr Lys 130 135 140 Thr Ala Thr Tyr Lys Val Val Arg Thr Val Pro Lys His Val Phe Glu 145 150 155 160 15 Thr Ala Arg Gly Val Leu Tyr Pro Gly Val Ser Asp Met Tyr Asp Ala 165 170 175 Lys Gln Tyr Val LYS Pro Val Asn Asn Ser Trp Ser Thr Asn Ala Gln 20 180 185 190 His Met Asn Phe Gin Phe Val Gly Thr Tyr Gly Pro Asn Lys Asp Val 195 200 205 25 Val Gly Tie Ser Thr Arg Leu Ile Arg Val Thr Tyr Asp Asn Arg Gin 210 215 220 Thr Glu Asp Lou Thr Ile Lou Ser Lys Val Lys Pro Asp Pro Pro Arg 225 230 235 240 30 Ile Asp Ala Asn Ser Val Thr Tyr Lys Ala Gly Leu Thr Asn Gin Glu 245 250 255 Ile Lys Val Asn Asn Val Leu Asn Asn Ser Ser Val Lys Leu Phe Lys 35 260 265 270 Ala Asp Asn Thr Pro Lou Asn Val Thr Asn Ile Thr His Gly Ser Gly 275 280 285 40 Phe Ser Ser Val Val Thr Val Ser Asp Ala Leu Pro Asn Gly Gly Ile 290 295 300 Lys Ala Lys Ser Ser Ile Ser Met Asn Asn Val Thr Tyr Thr Thr Gln 305 310 315 320 Asp Glu His Gly Gln Val Val Thr Val Thr Arg Asn Glu Ser Val Asp 325 330 335 Ser Asn Asp Ser Ala Thr Val Thr Val Thr Pro Gin Leu Gin Ala Thr 50 340 345 350 Thr Giu Giy Ala Val Phe Ile Lys Gly Gly Asp Gly Phe Asp Phe Gly 355 360 365 55 His Val Glu Arg Phe Ile Gin Asn Pro Pro His Gly Ala Thr Val Ala 370 375 380 Trp His Asp Ser Pro Asp Thr Trp Lys Asn Thr Val Gly Asn Thr His 385 390 395 400 Lys Thr Ala Val Val Thr Leu Pro Asn Giy Gin Gly Thr Arg Asn Val 405 410 415 45 60 36 2013205400 24 Apr 2013 Val Ala Gly Ile Ala 670 Thr Phe Asn Pro Ala 685 Gly Glu Thr Val Ser 700 Gly Thr Asp Thr Asp Glu Glu Val Pro Val Lys Val 420 Arg Asp Val Lys Gly Gin 5 435 Tyr Ile Thr Phe Asp Pro 450 10 Trp Ala Asn Arg Gin Gin 465 470 Tyr Pro Val Ala Asn Ala Lys Ala Pro Ser 425 430 Asn Leu Thr Asn Gly Thr Asp Ala Met Asn 94D 445 Asn Thr Asn Thr Asn Gly Ile Thr Ala Ala 455 960 Pro Asn Asn Gin Gin Ala Gly Val Gin His 475 480 Leu Asn Val Asp Val Thr Tyr Pro Gly Ile Ser Ala Ala Lys Arg Val 485 490 495 15 Pro Val Thr Val Asn Val Tyr Gln Phe Glu Phe Pro Gin Thr Thr Tyr 500 505 510 Thr Thr Thr Val Gly Gly Thr Leu Ala Ser Gly Thr Gln.Ala Ser Gly 20 515 520 525 Tyr Ala His Met Gin Asn Ala Thr Gly Leu Pro Thr Asp Gly Phe Thr 530 535 540 25 Tyr Lys Trp Asn Arg Asp 545 550 Thr Thr Gly Thr Asn Asp Ala Asn Trp Ser 555 560 Ala Met Asn Lys Pro Asn 565 30 Val Ile Tyr Asn Gly His 580 Val Val Lys Asp Val Gin 35 595 Thr Phe Ala Thr Ser Leu Pro Ala 585 59D Pro Ala Lys Pro Thr Val Thr Glu 600 605 Ala Gly 610 40 His Ala 625 Val Ala Lys Val Val Asn Ala Lys Tyr Asp 570 575 Ala Ile Thr Ile Ala Pro Gly Ala 615 Gly Asn Val Thr Thr Tyr Ala Asp 630 Asn Val Val Thr Thr Phe Thr Arg Arg 650 Asn Gin Thr Val 620 Lys Leu Val Ile Lys Arg 635 640 Asn Asn Thr Ser Pro 655 Lys Phe Thr Ala Asn Thr 645 Lys Glu Ala Ser Ala Ala Thr 660 665 Gly Ile Thr Val Ala Ala Gly 675 680 Ala Pro Gin Pro Asn Gln Ala 715 720 Ile Asp Ile Thr Pro Asn Asn 730 735 Gin Ala Met Asp Ile Ala Tyr Pro Ser Gly His Leu Ile Asn Pro Thr 790 795 75D Asn Gly 45 Trp Val Asn Asn 50 Ile Gln Val Val Ala Thr Gin Gly Ser 690 695 55 Gln Arg Ser Asp Asp Phe Thr Val Val 705 710 Thr Thr Lys Ile Trp Gin Asn Gly His 725 60 37 2013205400 24 Apr 2013 Thr Glu Lys Val Gly Asn Gly Ala Glu His Ser Lys Thr Ile Asn Val 755 760 765 Val Arg Gly Gin Asn Asn Gin Trp Thr Ile Ala Asn Lys Pro Asp Tyr 5 770 775 780 Val Thr Leu Asp Ala Gin Thr Gly Lys Val Thr Phe Asn Ala Asn Thr 785 790 795 800 10 Ile Lys Pro Asn Ser Ser Ile Thr Ile Thr Pro Lys Ala Gly Thr Gly 805 810 815 His Ser Val Her Her Asn Pro Her Thr Leu Thr Ala Pro Ala Ala His 820 825 830 15 Thr Val Asn Thr Thr Glu Ile Val Lys Asp Tyr Gly Ser Asn Val Thr 835 840 845 Ala Ala Glu Ile Asn Asn Ala Val Gln Val Ala Asn Lys Arg Thr Ala 20 850 855 860 Thr lie Lys Asn Gly Thr Ala Met Pro Thr Asn Leu Ala Gly Gly Ser 865 870 875 880 25 Thr Thr Thr Ile Pro Val Thr Val Thr Tyr Asn Asp Gly Ser Thr Glu 885 890 895 Glu Val Gln Glu Ser Ile Phe Thr Lys Ala Asp Lys Arg Glu Leu Ile 900 905 910 Thr Ala Lys Asn His Leu Asp Asp Pro Val Ser Thr Glu Gly Lys Lys 915 920 925 Pro Gly Thr Ile Thr Gln Tyr Asn Asn Ala Met His Asn Ala Gin Gin 35 930 935 940 Gln Ile Asn Thr Ala Lys Thr Glu Ala Gin Gin Val Ile Asn Asn Glu 945 950 955 960 40 Arg Ala Thr Pro Gln Gin Val Ser Asp Ala Leu Thr Lys Val Arg Ala 965 970 975 Ala Gin Thr Lys Ile Asp Gin Ala Lys Ala Leu Leu Gin Asn Lys Glu 980 985 990 45 Asp Asn Ser Gln Leu Val Thr Her Lys Asn Asn Leu Gin Her Ser Val 995 1000 1005 Asn Gin Val Pro Her Thr Ala Gly Met Thr Gin Gin Ser Ile Asp Asn 50 1010 1015 1020 Tyr Asn Ala Lys Lys Arg Glu Ala Glu Thr Glu Ile Thr Ala Ala Gin 1025 1030 1035 1040 55 Arg Val Ile Asp Asn Gly Asp Ala Thr Ala Gin Gin Ile Ser Asp Glu 1045 1050 1055 Lys His Arg Val Asp Asn Ala Leu Thr Ala Leu Asn Gln Ala Lys His 1060 1065 1070 60 Asp Leu Thr Ala Asp Thr His Ala Leu Glu Gin Ala Val Gin'Gln Leu 1075 1080 1085 30 38 2013205400 24 Apr 2013 Asn Arg Thr Gly Thr Thr Thr Gly Lys Lys Pro Ala Ser Ile Thr Ala 1090 1095 1100 Tyr Asn Asn Ser Ile Arg Ala Leu Gin Her Asp Leu Thr Ser Ala Lys 5 1105 1110 1115 1120 Asn Ser Ala Asn Ala Ile Ile Gin Lys Pro lie Arg Thr Val Gin Glu 1125 1130 1135 10 Val Gin Ser Ala Leu Thr Asn Val Asn Arg Val Asn Glu Arg Leu Thr 1140 1145 1150 Gin Ala Ile Asn Gln Leu Val Pro Leu Ala Asp Asn Ser Ala Leu Lys 1155 1160 1165 15 Thr Ala Lys Thr Lys Leu Asp Glu Glu Ile Asn Lys Ser Val Thr Thr 1170 1175 1180 Asp Gly Met Thr Gin Ser Her Ile Gln Ala Tyr Glu Asn Ala Lys Arg 20 1185 1190 1195 1200 Ala Gly Gln Thr Glu Ser Thr Asn Ala Gin Asn Val Ile Asn Asn Gly 1205 1210 1215 25 Asp Ala Thr Asp Gln Gin Ile Ala Ala Glu Lys Thr Lys Val Glu Glu 1220 1225 1230 Lys Tyr Asn Ser Leu Lys Gin Ala Ile Ala Gly Leu Thr Pro Asp Leu 1235 1240 1245 30 Ala Pro Leu Gin Thr Ala Lys Thr Gin Leu Gin Asn Asp Ile Asp Gln 1250 1255 1260 Pro Thr Ser Thr Thr Gly Met Thr Ser Ala Ser Ile Ala Ala Phe Asn 35 1265 1270 1275 1280 Glu Lys Leu Ser Ala Ala Arg Thr Lys Ile Gin Glu Ile Asp Arg Val 1285 1290 1295 40 Leu Ala Ser His Pro Asp Val Ala Thr Ile Arg Gin Asn Val Thr Ala 1300 1305 1310 Ala Asn Ala Ala Lys Ser Ala Leu Asp Gin Ala Arg Asn Gly Leu Thr 1315 1320 1325 45 Val Asp Lys Ala Pro Leu Glu Asn Ala Lys Asn Gln Leu Gln Tyr Her 1330 1335 1340 Ile Asp Thr Gin Thr Ser Thr Thr Gly Met Thr Gin Asp Ser Ile Asn 50 1345 1350 1355 1360 Ala Tyr Asn Ala Lys Leu Thr Ala Ala Arg Asn Lys Ile Gin Gin Ile 1365 1370 1375 55 Asn Gln Val Leu Ala Gly Ser Pro Thr Val Glu Gin Ile Asn Thr Asn 1380 1385 1390 Thr Her Thr Ala Asn Gin Ala Lys Ser Asp Leu Asp His Ala Arg Gin 1395 1400 1405 60 Ala Leu Thr Pro Asp Lys Ala Pro Leu Gln Thr Ala Lys Thr Gin Leu 1410 1415 1420 39 2013205400 24 Apr 2013 Giu Gin Ser Ile Asn Gin Pro Thr Asp Thr Thr Gly Met Thr Thr Ala 1425 1430 1435 1440 Ser Leu Asn Ala Tyr Asn Gln Lys Leu Gin Ala Ala Arg Gin Lys Leu 1445 1450 1455 Thr Giu Ile Asn Gin Val Leu Asn Gly Asn Pro Thr Val Gin Asn Ile 1460 1465 1470 10 Asn Asp Lys Val Thr Giu Ala Asn Gin Ala Lys Asp Gin Leu Asn Thr 1475 1480 1485 Ala Arg Gin Gly Len Thr Leu Asp Arg Gin Pro Ala Leu Thr Thr Leu 1490 1495 1500 15 His Gly Ala Ser Asn Leu Asn Gin Ala Gin Gin Asn Asn Phe Thr Gln 1505 1510 1515 1520 Gin Ile Asn Ala Ala Gin Asn His Ala Ala Leu Glu Thr Ile Lys Ser 20 1525 1530 1535 Asn Ile Thr Ala Len Asn Thr Ala Met Thr Lys Leu Lys Asp Ser Val 1540 1545 1550 25 Ala Asp Asn Asn Thr Ile Lys Ser Asp Gin Asn Tyr Thr Asp Ala Thr 1555 1560 1565 Pro Ala Asn Lys Gin Ala Tyr Asp Asn Ala Val Asn Ala Ala Lys Gly 1570 1575 1580 30 Val Ile Gly Glu Thr Thr Asn Pro Thr Met Asp Val Asn Thr Val Asn 1585 1590 1595 1600 Gin Lys Ala Ala Ser Val Lys Ser Thr Lys Asp Ala Leu Asp Gly Gin 35 1605 1610 1615 Gln Asn Leu Gin Arg Ala Lys Thr Glu Ala Thr Asn Ala Ile Thr His 1620 1625 1630 40 Ala Ser Asp Leu Asn Gin Ala Gin Lys Asn Ala Leu Thr Gin Gin Val 1635 1640 1645 Asn Ser Ala Gln Asn Val Gin Ala Val Asn Asp Ile Lys Gln Thr Thr 1650 1655 1660 45 Gin Ser Leu Asn Thr Ala Met Thr Gly Leu Lys Arg Gly Val Ala Asn 1665 1670 1675 1680 His Asn Gin Val Val Gin Ser Asp Asn Tyr Val Asn Ala Asp Thr Asn 50 1685 1690 1695 Lys Lys Asn Asp Tyr Asn Asn Ala Tyr Asn His Ala Asn Asp Ile Ile 1700 1705 1710 55 Asn Gly Asn Ala Gin His Pro Val Ile Thr Pro Ser Asp Val Asn Asn 1715 1720 1725 Ala Leu Ser Asn Val Thr Ser Lys Glu His Ala Len Asn Gly Glu Ala 1730 1735 1740 60 Lys Leu Asn Ala Ala Lys Gin Giu Ala Asn Thr Ala Leu Gly His Leu 1745 1750 1755 1760 40 2013205400 24 Apr 2013 Asn Asn Leu Asn Asn Ala Gin Arg Gin Asn Leu Gin Ser Gln Ile Asn 1765 1770 1775 Gly Ala His Gin Ile Asp Ala Val Asn Thr Ile Lys Gin Asn Ala Thr 5 1760 1785 1790 Asn Leu Asn Ser Ala Met Gly Asn Leu Arg Gin Ala Val Ala Asp Lys 1795 1900 1805 10 Asp Gin Val Lys Arg Thr Glu Asp Tyr Ala Asp Ala Asp Thr Ala Lys 1810 1815 1820 Gin Asn Ala Tyr Asn Ser Ala Val Ser Sex Ala Glu Thr Ile Ile Asn 1825 1830 1835 1840 15 Gln Thr Thr Asn Pro Thr Met Ser Val Asp Asp Val Asn Arg Ala Thr 1845 1850 1855 Sex Ala Val Thr Sex Asn Lys Asn Ala Leu Asn Giy Tyr Glu Lys Leu 20 1860 1865 1870 Ala Gln Ser Lys Thr Asp Ala Ala Arg Ala Ile Asp Ala Leu Pro His 1875 1880 1885 25 Leu Asn Asn Ala Gin Lys Ala Asp Val Lys Ser Lys Ile Asn Ala Ala 1890 1895 1900 Ser Asn Ile Ala Gly Val Asn Thr Val Lys Gln Gln Gly Thr Asp Leu 1905 1910 1915 1920 30 Asn Thr Ala Met Gly Asn Leu Gin Gly Ala Ile Asn Asp Glu Gin Thr 1925 1930 1935 Thr Leu Asn Ser Gin Asn Tyr Gin Asp Ala Thr Pro Sex Lys Lys Thr 35 1940 1945 1950 Ala Tyr Thr Asn Ala Val Gln Ala Ala Lys Asp Ile Leu Asn Lys Ser 1955 1960 1965 40 Asn Gly Gin Asn Lys Thr Lys Asp Gin Val Thr Glu Ala Met Asn Gln 1970 1975 1980 Val Asn Ser Ala Lys Asn Asn Leu Asp Gly Thr Arg Leu Leu Asp Gln 1985 1990 1995 2000 45 Ala Lys Gln Thr Ala Lys Gin Gin Leu Asn Asn Met Thr His Leu Thr 2005 2010 2015 Thr Ala Gln Lys Thr Asn Leu Thr Asn Gin Ile Asn Ser Gly Thr Thr 50 2020 2025 2030 Val Ala Gly Val Gin Thr Val Gin Ser Asn Ala Asn Thr Leu Asp Gln 2035 2040 2045 55 Ala Met Asn Thr Leu Arg Gin Ser Ile Ala Asn Lys Asp Ala Thr Lys 2050 2055 2060 Ala Ser Giu Asp Tyr Val Asp Ala Asn Asn Asp Lys Gin Thr Ala Tyr 2065 2070 2075 2080 60 Asn Asn Ala Val Ala Ala Ala Glu Thr Ile Ile Asn Ala Asn Sex Asn 2085 2090 2095 41 2013205400 24 Apr 2013 Pro Glu Met Asn Pro Ser Thr Ile Thr Gin Lys Ala Glu Gin Val Asn 2100 2105 2110 Her Ser Lys Thr Ala Leu Asn Gly Asp Glu Asn Leu Ala Ala Ala Lys 5 2115 2120 2125 Gln Asn Ala Lys Thr Tyr Leu Asn Thr Leu Thr Ser Ile Thr Asp Ala 2130 2135 2140 10 Gin Lys Asn Asn Leu Ile Ser Gin Ile Thr Ser Ala Thr Arg Val Ser 2145 2150 2155 2160 Gly Val Asp Thr Val Lys Gin Asn Ala Gin His Leu Asp Gin Ala Met 2165 2170 2175 Ala Ser Leu Gin Asn Gly Ile Asn Asn Glu Ser Gin Val Lys Ser Ser 2180 2185 2190 Glu Lys Tyr Arg Asp Ala Asp Thr Asn Lys Gin Gin Giu Tyr Asp Asn 2195 2200 2205 Ala Ile Thr Ala Ala Lys Ala Ile Leu Asn Lys Ser Thr Gly Pro Asn 2210 2215 2220 25 Thr Ala Gin Asn Ala Val Glu Ala Ala Leu Gln Arg Val Asn Asn Ala 2225 2230 2235 2240 Lys Asp Ala Leu Asn Gly Asp Ala Lys Leu Ile Ala Ala Gln Asn Ala 2245 2250 2255 30 Ala Lys Gin His Leu Gly Thr Leu Thr His Ile Thr Thr Ala Gin Arg 2260 2265 2270 Asn Asp Leu Thr Asn Gin Ile Ser Gin Ala Thr Asn Leu Ala Gly Val 35 2275 2280 2285 Giu Ser Val Lys Gin Asn Ala Asn Ser Leu Asp Gly Ala Met Gly Asn 2290 2295 2300 40 Leu Gln Thr Ala Ile Asn Asp Lys Ser Gly Thr Leu Ala Ser Gln Asn 2305 2310 2315 2320 Phe Leu Asp Ala Asp Glu Gln Lys Arg Asn Ala Tyr Asn Gin Ala Val 2325 2330 2335 45 Ser Ala Ala Glu Thr Ile Leu Asn Lys Gin Thr Gly Pro Asn Thr Ala 2340 2345 2350 Lys Thr Ala Val Giu Gin Ala Leu Asn Asn Val Asn Asn Ala Lys His 50 2355 2360 2365 Ala Leu Asn Gly Thr Gin Asn Leu Asn Asn Ala Lys Gin Ala Ala Ile 2370 2375 2380 55 Thr Ala Ile Asn Gly Ala Ser Asp Leu Asn Gin Lys Gin Lys Asp Ala 2385 2390 2395 2400 Leu Lys Ala Gin Ala Asn Gly Ala Gin Arg Val Ser Asn Ala Gln Asp 2405 2410 2415 60 Val Gin His Asn Ala Thr Glu Leu Asn Thr Ala Met Gly Thr Leu Lys 2420 2425 2430 15 20 42 2013205400 24 Apr 2013 His Ala Ile Ala Asp Lys Thr Asn Thr Leu Ala Ser Ser Lys Tyr Val 2435 2440 2445 Asn Ala Asp Ser Thr Lys Gln Asn Ala Tyr Thr Thr Lys Val Thr Asn 5 2450 2455 2460 Ala Glu His Ile Ile Ser Gly Thr Pro Thr Val Val Thr Thr Pro Ser 2465 2470 2475 2480 10 Glu Val Thr Ala Ala Ala Asn Gin Val Asn Ser Ala Lys Gin Glu Leu 2485 2490 2495 Asn Gly Asp Glu Arg Leu Arg Glu Ala Lys Gin Asn Ala Asn Thr Ala 2500 2505 2510 15 Ile Asp Ala Leu Thr Gin Leu Asn Thr Pro Gin Lys Ala Lys Leu Lys 2515 2520 2525 Glu Gin Val Gly Gin Ala Asn Arg Leu Glu Asp Val Gln Thr Val Gin 20 2530 2535 2540 Thr Asn Gly Gln Ala Leu Asn Asn Ala Met Lys Gly Leu Arg Asp Ser 2545 2550 2555 2560 25 Ile Ala Asn Glu Thr Thr Val Lys Thr Sex Gin Asn Tyr Thr Asp Ala 2 2570 2575 2565 Ser Pro Asn Asn Gln Ser Thr Tyr Asn Sex Ala Val Ser Asn Ala Lys 2580 2585 2590 Gly Ile Ile Asn Gin Thr Asn Asn Pro Thr Met Asp Thr Ser Ala Ile 2595 2600 2605 Thr Gln Ala Thr Thr Gin Val Asn Asn Ala Lys Asn Gly Leu Asn Gly 35 2610 2615 2620 Ala Glu Asn Leu Arg Asn Ala Gin Asn Thr Ala Lys Gln Asn Leu Asn 2625 2630 2635 2640 40 Thr Leu Ser His Leu Thr Asn Asn Gin Lys Ser Ala Ile Ser Ser Gin 2645 2650 2655 Ile Asp Arg 30 45 <210> 29 <211> 496 <212 .> PRT 50 <213> Staphylococcus aureus <400> 29 Met Asn Met Lys Lys Lys Glu Lys His Ala lie Arg Lys Lys Ser Ile 1 5 10 15 55 Gly Val Ala Ser Val Leu Val Gly Thr Leu Ile Gly Phe Gly Leu Leu 20 25 30 Ser Ser Lys Glu Ala Asp Ala Ser Glu Asn Ser Val Thr Gin Ser Asp 60 35 40 45 Ser Ala Ser Asn Glu Ser Lys Ser Asn Asp Ser Ser Ser Val Ser Ala 50 55 60 43 2013205400 24 Apr 2013 Ala Pro Lys Thr Asp Asp Thr Asn Val Ser Asp Thr Lys Thr Ser Ser 65 70 75 80 5 Asn Thr Asn Asn Gly Glu Thr Ser Val Ala Gin Asn Pro Ala Gin Gin 85 90 95 Glu Thr Thr Gln Set Ser Ser Thr Asn Ala Thr Thr Glu Glu Thr Pro 100 105 110 10 Val Thr Gly Giu Ala Thr Thr Thr Thr Thr Asn Gin Ala Asn Thx Pro 115 120 125 Ala Thr Thr Gin Set Ser Asn Thr Asn Ala Glu Glu Leu Val Asn Gin 15 130 135 140 Thr Ser Asn Glu Thr Thr Phe Asn Asp Thr Asn Thr Val Sex- Set Val 145 150 155 160 20 Asn Set Pro Gin Asn Ser Thr Asn Ala Glu Asn Val Ser Thr Thr Gln 165 170 175 Asp Thr Ser Thr GlU Ala Thr Pro Ser Asn Asn Glu Ser Ala Pro Gin 180 185 190 Ser Thr Asp Ala Ser Asn Lys Asp Val Val Asn Gln Ala Val Asn Thr 195 200 205 Set Ala Pro Arg Met Arg Ala Phe Ser Leu Ala Ala Val Ala Ala Asp 30 210 215 220 Ala Pro Ala Ala Gly Thr Asp Ile Thr Asn Gln Leu Thr Asn Val Thz 225 230 235 240

35. Val Gly Ile Asp Sez Gly Thr Thr Val Tyr Pro His Gin Ala Gly Tyr 245 250 255 Val Lys Leu Asn Tyr Gly Phe Sex Val Pro Asn Ser Ala Val Lys Gly 260 265 270 40 Asp Thr Phe Lys Ile Thr Val Pro Lys Glu Leu Asn Leu Asn Gly Val 275 280 285 Thr Ser Thr Ala Lys Val Pro Pro Ile Met Ala Gly Asp Gin Val Leu 45 290 295 300 Ala Asn Gly Val Ile Asp Ser Asp Gly Asn Val Ile Tyr Thr Phe . Thr 305 310 315 320 50 Asp Tyr Val Asn Thr Lys Asp Asp Val Lys Ala Thr Leu Thr Met Pro 325 330 335 Ala Tyr Ile Asp Pro Glu Asn Val Lys Lys Thr Gly Asn Val Thr Leu 340 345 350 55 Ala Thr Gly Ile Gly Ser Thr Thr Ala Asn Lys Thr Val Leu Val Asp 355 360 365 Tyr Glu Lys Tyr Gly Lys Phe Tyr Asn Leu Set Ile Lys Gly Thr Ile 60 370 375 380 Asp Gin Ile Asp Lys Thr Asn Asn Thr Tyr Arg Gin Thr Ile Tyr Val 385 390 395 400 25 44 2013205400 24 Apr 2013 Asn Pro Ser Gly Asp Asn Val Ile Ala Pro Val Leu Thr Gly Asn Leu 405 410 415 5 Lys Pro Asn Thr Asp Ser Asn Ala Leu Ile Asp Gln Gln Asn Thr Ser 420 425 430 Ile Lys Val Tyr Lys Val Asp Asn Ala Ala Asp Leu Ser Glu Sex Tyr 435 440 445 10 Phe Val Asn Pro Glu Asn Phe Glu Asp Val Thr Asn Ser Val Asn Ile 450 455 460 Thr Phe Pro Asn Pxo Asn Gin Tyr Lys Val Glu Phe Asn Thr Pro Asp 15 465 470 475 480 Asp Gin Ile Thr Thr Pro Tyr Ile Val Val Val Asn Gly His Ile Asp 485 490 495 20 <210> 30 25 <211> 541 <212> PRT <213> Staphylococcus aureus <400> 30 30 Asp Gln Tyr Leu Leu Glu Arg Lys Lys Ser Gin Tyr Glu Asp Tyr Lys 1 5 10 15 Gin Trp Tyr Ala Asn Tyr Lys Lys Glu Asn Pro Arg Thr Asp Leu Lys 20 25 30 35 Met Ala Asn Phe His Lys Tyr Asn Leu Glu Glu Leu Her Met Lys Glu 35 40 45 Tyr Asn Glu Leu Gln Asp Ala Leu Lys Arg Ala Leu Asp Asp Phe His 40 50 55 60 Arg Glu Val Lys Asp Ile Lys Asp Lys Asn Ser Asp Leu Lys Thr Phe 65 70 75 80 45 Asn Ala Ala Glu Glu Asp Lys Ala Thr Lys Glu Val Tyr Asp Leu Val 85 90 95 Ser Glu Ile Asp Thr Leu Val Val Ser Tyr Tyr Gly Asp Lys Asp Tyr 100 105 110 50 Gly Glu His Ala Lys Glu Leu Arg Ala Lys Leu Asp Leu Ile Leu Gly 115 120 125 Asp Thr Asp Asn Pro His Lys Ile Thr Asn Glu Arg Ile Lys Lys Glu 55 130 135 140 Met Ile Asp Asp Leu Asn Ser Ile Ile Asp Asp Phe Phe Met Giu Thr 145 150 155 160 60 Lys Gin Asn Arg Pro Lys Ser Ile Thr Lys Tyr Asn Pro Thr Thr His 165 170 175 Asn Tyr Lys Thr Asn Ser Asp Asn Lys Pro Asn Phe Asp Lys Leu Val 45 2013205400 24 Apr 2013 180 185 190 Glu Glu Thr Lys Lys Ala Val Lys Gln Ala Asp Asp Sex Trp Lys Lys 195 200 205 5 Lys Thr Val Lys Lys Tyr Gly Glu Thr Gln Thr Lys Ser Pro Val Val 210 215 220 Lys Glu Glu Lys Lys Val Glu Glu Pro Gln Ala Pro Lys Val Asp Asn 10 225 230 235 240 Gln Gin Glu Val Lys Thr Thr Ala Gly Lys Ala Gin Gin Thr Thr Gln 245 250 255 15 Pro Val Ala Gln Pro Leu Val Lys Ile Pro Gin Gly Thr Ile Thr Gly 260 265 270 Gin Ile Val Lys Giy Pro Gln Tyr Pro Thr Met Gin Asn Lys Thr Val 275 280 285 20 Gln Gly Glu Ile Val Gin Gly Pro Asp Phe Leu Thr Met Glu Gln Ser 290 295 300 Gly Pro Ser Leu Ser Asn Asn Tyr Thr Asn Pro Pro Leu Thr Asn Pro 25 305 310 315 320 Ile Leu Glu Gly Leu Glu Gly Ser Ser Ser Lys Len Glu Ile Lys Pro 325 330 335 30 Gin Gly Thr Glu Ser Thr Len Lys Giy Thr Gin Gly Glu Ser Ser Asp 340 345 350 Ile Glu Val Lys Pro Gin Ala Thr Glu Thr Thr Glu Ala Ser Gln Tyr 355 360 365 Gly Pro Arg Pro Gin Phe Asn Lys Thr Pro Lys Tyr Val Lys Tyr Arg 370 375 380 Asp Ala Gly Thr Gly Ile Arg Glu Tyr Asn Asp Gly Thr Phe Gly Tyr 40 385 390 395 400 Glu Ala Arg Pro Arg Phe Asn Lys Pro Ser Glu Thr Asn Ala Tyr Asn 405 410 415 45 Val Thr Thr His Ala Asn Giy Gin Val Ser Tyr Gly Ala Arg Pro Thr 420 425 430 Tyr Lys Lys Pro Ser Gin Thr Asn Ala Tyr Asn Val Thr Thr His Ala 435 440 445 50 Asn Gly Gin Val Ser Tyr Giy Ala Arg Pro Thr Gin Asn Lys Pro Ser 450 455 460 Lys Thr Asn Ala Tyr Asn Val Thr Thr His Gly Asn Gly Gin Val Ser 55 465 470 475 480 Tyr Gly Ala Arg Gln Ala Gin Asn Lys Pro Ser Lys Thr Asn Ala Tyr 485 490 495 60 Asn Val Thr Thr His Ala Asn Giy Gin Val Ser Tyr Gly Ala Arg Pro 500 505 510 Thr Tyr Lys Lys Pro Ser Lys Thr Asn Ala Tyr Asn Val Thr Thr His 35 46 2013205400 24 Apr 2013 515 520 525 Ala Asp Gly Thr Ala Thr Tyr Gly Pro Arg Val Thr Lys 530 535 540 5 <210> 31 <211> 356 <212> PRT 10 <213> Staphylococcus aureus <400> 31 Met Lys Met Arg Thr Ile Ala Lys Thr Ser Leu Ala Leu Gly Leu Leu 1 5 10 15 Thr Thr Gly Ala Ile Thr Val Thr Thr Gin Ser Val. Lys Ala Glu Lys 20 25 30 Ile Gin Ser Thr Lys Val Asp Lys Val Pro Thr Leu Lys Ala Glu Arg 35 40 45 Leu Ala Met Ile Asn Ile Thr Ala Gly Ala Asn Ser Ala Thr Thr Gin 50 55 60 25 Ala Ala Asn Thr Arg Gln Glu Arg Thr Pro Lys Leu Glu Lys Ala Pro 65 70 75 80 Asn Thr Asn Glu Glu Lys Thr Ser Ala Ser Lys Ile Glu Lys Ile Ser 85 90 95 Gin Pro Lys Gln Glu Glu Gin Lys Thr Leu Asn Ile Ser Ala Thr Pro 100 105 110 Ala Pro Lys Gin Glu Gin Ser Gln Thr Thr Thr Glu Ser Thr Thr Pro 115 120 125 Lys Thr Lys Val Thr Thr Pro Pro Ser. Thr Asn Thr Pro Gin Pro Met 130 135 140 40 Gin Ser Thr Lys Ser Asp Thr Pro Gin Ser Pro Thr Ile Lys Gln Ala 145 I5D 155 160 Gin Thr Asp Met Thr Pro Lys Tyr Glu Asp Leu Arg Ala Tyr Tyr Thr 165 170 175 45 Lys Pro Ser Phe Glu Phe Glu Lys Gin Phe Gly Phe Met Leu Lys Pro 180 185 190 Trp Thr Thr Val Arg Phe Met Asn Val Ile Pro Asn Arg Phe Ile Tyr 50 195 200 205 Lys Ile Ala Leu Val Gly Lys Asp Glu Lys Lys Tyr Lys Asp Gly Pro 210 215 220 55 Tyr Asp Asn Ile Asp Val Phe Ile Val Leu Glu Asp Asn Lys Tyr Gln 225 230 235 240 Leu Lys Lys Tyr Ser Val Gly Gly Ile Thr Lys Thr Asn Ser Lys Lys 245 250 255 60 Val Asn His Lys Val Glu Leu Ser Ile Thr Lys Lys Asp Asn Gin Gly 260 265 270 15 20 30 35 47 2013205400 24 Apr 2013 Met Ile Ser Arg Asp Val Ser Glu Tyr Met Ile Thr Lys Glu Glu Ile 275 280 285 Ser Leu Lys Glu Leu Asp Phe Lys Leu Arg Lys Gln Leu Ile Glu Lys 5 290 295 300 His Asn Leu Tyr Gly Asn Met Gly Ser Gly Thr Ile Val Ile Lys Met 305 310 315 320 10 Lys Asn Gly Giy Lys Tyr Thr Phe Glu Leu His Lys Lys Leu Gin Glu 325 330 335 His Arg Met Ala Asp Val Ile Asp Gly Thr Asn Ile Asp Asn Ile Glu 340 345 350 15 Val Asn Ile Lys 355 20 <210> 32 <211> 313 <212> PRT <213> Staphylococcus aureus 25 <400> 32 Met Glu His Thr Thr Met Lys Ile Thr Thr Ile Ala Lys Thr Ser Leu 1 5 10 15 Ala Leu Gly Leu Leu Thr Thr Gly Val Ile Thr Thr Thr Thr Gin Ala 30 20 25 30 Ala Asn Ala Thr Thr Leu Ser Ser Thr Lys Val Glu Ala Pro Gin Ser 35 40 45 35 Thr Pro Pro Ser Thr Lys Ile Glu Ala Pro Gin Ser Lys Pro Asn Ala 50 55 60 Thr Thr Pro Pro Ser Thr Lys Val Glu Ala Pro Gin Gln Thr Ala Asn 65 70 75 80 40 Ala Thr Thr Pro Pro Ser Thr Lys Val Thr Thr Pro Pro Ser Thr Asn 85 90 95 Thr Pro Gin Pro Met Gln Ser Thr Lys Ser Asp Thr Pro Gln Ser Pro 45 100 105 110 Thr Thr Lys Gin Val Pro Thr Glu Ile Asn Pro Lys Phe Lys Asp Leu 115 120 125 50 Arg Ala Tyr Tyr Thr Lys Pro Ser Leu Glu Phe Lys Asn Giu Ile Gly 130 135 140 Ile Ile Leu Lys Lys Trp Thr Thr Ile Arg Phe Met Asn Val Val Pro 145 150 155 160 55 Asp Tyr Phe Ile Tyr Lys Ile Ala Leu Val Gly Lys Asp Asp Lys Lys 165 170 175 Tyr Gly Glu Gly Val His Arg Asn Val Asp Val Phe Val Val Leu Glu 60 180 185 190 Glu Asn Asn Tyr Asn Leu Glu Lys Tyr Ser Val Giy Giy Ile Thr Lys 195 200 205 48 2013205400 24 Apr 2013 Her Asn Ser Lys Lys Val Asp His Lys Ala Gly Val Arg Ile Thr Lys 210 215 220 5 Glu Asp Asn Lys Gly Thr Ile Ser His Asp Val Ser Glu Phe Lys Ile 225 ' 230 235 240 Thr Lys Glu Gln Ile Ser Leu Lys Glu Leu Asp Phe Lys Leu Arg Lys 245 250 255 10 Gin Leu Ile Glu Lys Asn Asn Leu Tyr Gly Asn Val Gly Ser Gly Lys 260 265 270 Ile Val Ile Lys Met Lys Asn Gly Gly Lys Tyr Thr Phe Glu Leu His 15 275 280 285 Lys Lys Leu Gin Glu Asn Arg Met Ala Asp Val Ile Asp Gly Thr Asn 290 295 300 20 Ile Asp Asn Ile Glu Val Asn Ile Lys 305 310 25 30 35 40 45 50 55 60 49 2013205400 24 Apr 2013